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Abstract
Chromosomal instability—a hallmark of epithelial cancers—is an ongoing process that results in aneuploidy and
karyotypic heterogeneity of a cancer cell population. Previously, we stratified cancer cell lines in the NCI-60 drug
discovery panel based on their karyotypic complexity and heterogeneity. Using this stratification in conjunction
with drug response data for the cell lines allowed us to identify classes of chemical compounds whose growth-
inhibitory activity correlates with karyotypic complexity and chromosomal instability. In this article, we asked the
question: What are the biological processes, pathways, or genes associated with chromosomal instability of can-
cer cells? We found that increased instability of the chromosomal content in a cancer cell population, particularly,
persistent gains and losses of chromosomes, is associated with elevated expression of genes involved with
aggressive cellular behavior, including invasion- and metastasis-associated changes in cell communication, ad-
hesion, motility, and migration. These same karyotypic features are negatively correlated with the expression of
genes involved in cell cycle checkpoints, DNA repair, and chromatin maintenance.
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Introduction
Most cancers have an abnormal chromosomal content characterized by
changes in chromosomal structure and number. Chromosomal aberra-
tions tend to be more numerous in malignant tumors than in benign
ones [1,2], and karyotypic complexity is associated with aggressive
clinical behavior of tumors and poor prognoses [3–5]. Cancers contain
cells that not only possess an abnormal number of chromosomes but
also often show population heterogeneity with regard to the exact chro-
mosomal complement. That heterogeneity is a marker of ongoing chro-
mosomal instability in cancers—accelerated rates of gains and losses of
whole chromosomes or large portions of cancer cell genomes [6,7].
Chromosomal instability is a process that facilitates cancer cell evolu-
tion under selection pressure, and because of instability and selection,
tumors most frequently acquire an aneuploid chromosomal content.
The NCI-60 cancer cell line panel was assembled by the Develop-
mental Therapeutics Program of the National Cancer Institute for
in vitro anticancer drug screening. It includes human cancer cell lines
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of lung, renal, colorectal, ovarian, breast, prostate, central nervous
system (CNS), melanocyte, and hematological origins [8]. Since
1990, the NCI-60 cells have been exposed to more than 100,000 com-
pounds in short-term cytotoxicity assays (http://dtp.nci.nih.gov) [9],
and they have been profiled more extensively at the DNA, RNA, pro-
tein, and functional levels than any other set of cell lines [10]. Previ-
ously, we defined and studied karyotypic complexity and heterogeneity
(as markers of ongoing instability) in the NCI-60 [11] and used this
stratification to identify groups and classes of chemical compounds with
higher growth-inhibitory activity in the more karyotypically complex
and chromosomally unstable lines [12–14]. In the present work, we
ask the question: What biological processes, pathways, and genes are
associated with karyotypic instability of cancer cells? To address that
question, we analyzed the correlation between karyotypic parameters
and expression of genes across the NCI-60 panel.
Materials and Methods
Karyotypic Parameters of the NCI-60 Panel of Cancer
Cell Lines
The NCI-60 panel of cancer cell lines was developed by the Na-
tional Cancer Institute for in vitro anticancer drug screening, and it
included cell lineages derived from different tissues (lung, renal,
colorectal, ovarian, breast, prostate, CNS, melanoma, and hemato-
logical malignancies). Every cell line in the NCI-60 panel carries
karyotypic abnormalities with notable individual variations among
the cell lines at the level of karyotypic complexity and heterogeneity
[11]. Complexity of the karyotype was defined on the basis of nu-
merical abnormalities and structural rearrangements. Numerical
chromosomal complexity (NC) was expressed in relation to the cell
line ploidy level, according to the International System for Human
Cytogenetic Nomenclature convention, and was calculated as a sum
of the number of deviations of each specific chromosome from the
designated ploidy level. Structural chromosomal complexity (SC) was
expressed as the number of different structurally rearranged chromo-
somes present in two or more metaphases. Numerical chromosomal
heterogeneity (NH) corresponds to the number of cell-to-cell varia-
tions of similar chromosomes. Loss of a chromosome in only one
or two cells or gain in only one cell was not considered in the cal-
culation of numerical heterogeneity because of the possibility of
mechanical loss or gain during preparation of the metaphase spreads.
Any specific chromosome displaying a higher number of gains or
losses was considered to show variability and tallied as “1 point” in
the numerical heterogeneity index. Structural chromosomal hetero-
geneity (SH) was estimated as the number of nonclonal (i.e., present
in only one metaphase, according to the International System for
Human Cytogenetic Nomenclature convention) structurally abnor-
mal chromosomes per metaphase.
NCI-60 Gene Expression Data
We used mRNA expression databases for the NCI-60 cell lines from
the HG-U95 and the HG-U133 Affymetrix sets. HG-U95A data
set includes ∼12,000 array features corresponding to 8978 genes.
HG-U133 data set has ∼22,000 array features corresponding to
13,032 genes [15]. Gene expression data for NCI-60 cell lines were
generated by hybridization to U133A and U133B arrays (Affymetrix,
Santa Clara, CA), and CEL files were downloaded from http://discover.
nci.nih.gov/cellminer. Three cell lines were excluded from analysis for
different reasons (MDA-N was not available for karyotypic analysis,
NCI/ADR-RES was a derivative of OVCAR-8, and lung cancer cell
line H23 had no gene expression data available).
Data Analysis
CEL files for 57 cell lines were imported into R-2.4.0 language
and statistical computing environment [16] using the Affy package
of BioConductor-1.8 [17]. Probe set summarization, convolution
background correction, and quantile normalization were conducted
using a robust multichip average method [18] separately for U133A
and U133B array sets. Data were filtered to have expression measure-
ments to be above 16 in at least 25% of the samples and the inter-
quartile range across the samples to be at least 0.5 on log2 scale. This
nonspecific filtering leaves 7500 probe sets for the U133A array set
and 4036 probe sets for the U133B array set. Probe set expression
measurements (log2-transformed) were combined into one data
matrix (11,536 probe sets) that was transposed and aligned with
karyotypic characteristics of cell lines for analysis of Spearman’s rank
correlation between gene expression and karyotypic parameters.
To calculate the false discovery rate (FDR) for each Spearman
correlation coefficients (SCCs), 1000 random permutations of the
karyotypic characteristic value (NC, NH, SC, or SH) were per-
formed, and SCCs were recalculated for all 11,536 probe sets for
each permutation. The number of probe sets having an SCC with
a P value ≤ .001 per random permutation was used to estimate
FDR as the number of such probe sets at 0.95 or 0.99 quantiles
(corresponding percentiles were considered as confidence levels for
FDR estimates).
Genes differentially expressed in cell lines depending on tissue of
origin were identified separately for U133A and U133B arrays using
univariate F test as it is implemented in BRB-Array Tools [19].
Genes were considered differentially expressed if their F test para-
metric P value was less than .001.
To identify the most relevant GO terms associated with gene
lists, gene-GO term enrichment analysis was performed using the
DAVID2007 Functional Annotation Tool with customized gene
backgrounds [20,21].
Results
Correlation of Expression Profiles with Karyotypic Parameters
We obtained SCCs between karyotypic parameters (SC, SH, NC,
and NH) and each of the 11,536 probe sets from HG-U133A and
HG-U133B data set obtained after filtering. The highest number
of statistically significant (P < .001) correlations was identified for
NH (454 array elements corresponding to 360 genes), followed by
SH (318 array elements corresponding to 264 genes), NC (278 array
elements corresponding to 224 genes), and SC (54 array elements
corresponding to 50 genes; Table W1). To estimate the proportion
of false-positives, 1000 random permutations of NH, NC, SH, and
SC values were performed, and for each permutation, SCCs were cal-
culated for all 11,536 probe sets. The density distributions of the
number of SCCs with P value ≤ .001 for permuted sample were then
analyzed. With 99% confidence, among 454 array elements cor-
related with NH for which SCCs have P values .001 or less, there
were no more than 73 false-positive probe sets for which a positive
or negative correlation of expression measurements with NH may be
due to random variation in gene expression or NH (Table W1).
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Because NH correlates with the highest number of gene expression
profiles, and the number of possible false-positive results at P < .001 is
the lowest for this parameter, correlations with gene expression profiles
obtained for NH were chosen for further investigation.
Data for 454 probe sets for which the SCCs between NH and
gene expression had P value .001, are presented in Table W2. Vari-
ability in SCCs for these 454 array elements was estimated by draw-
ing 1000 bootstrap replicates and calculating the average bootstrap
SCCs and corresponding quantiles as confidence intervals. For all
454 array elements, 99% bootstrap confidence intervals of SCCs do
not include zero, remaining either positive or negative throughout.
Top Genes Associated with NH
Table 1 shows the top 50 Affy IDs positively associated with NH.
These 50 Affy IDs correspond to only 39 gene transcripts because
8 genes (ABL2, ATP6V0E, CRTAP, FN1, GNG12, IL13RA1,
TIMP2, and TNPO1) had more than one Affy ID selected in the
top 50 positive list. On the basis of the SCC and P value, the three
top genes with expression positively associated with NH are VEGFC,
leprecan-like 1, and Ras-related GTP-binding C (Table 1). The list of
50 positive top genes is significantly enriched with genes that control
cell communication (15 genes) and signal transduction (14 genes),
response to wounding and cell motility (6 genes), cytokine–cytokine
receptor interaction (5 genes), and cell migration (4 genes).
The top 50 Affy IDs (corresponding to 46 genes) expression of
which negatively correlated with NH are shown in the Table 1B.
In this top 50 negative list, NUP210 is represented by four Affy
IDs and BTBD16 is represented by two. Both are among the three
top genes negatively associated with NH. The third is MLLT6
(Table 1). Among all 46 gene transcripts, 26 are significantly associ-
ated with intracellular organelles, 22 have membrane-bound prod-
ucts, and 18 are related to the nucleus.
Identification of Origin-Independent Transcriptional
Changes Associated with NH
The NCI-60 panel includes cell lines derived from different tis-
sues. It seems possible, therefore, that the differences in gene expres-
sion profiles that correlate with karyotype are actually determined
by tissue of origin and that correlations with karyotypic parameters
simply reflect that fact epiphenomenally. Indeed, cluster analysis
(Supplementary Materials and Methods) shows that the main factor
that affects pattern of gene expression in the NCI-60 cell lines is the
tissue of origin of the cell line (Figures W1–W3). Even when we
selected for this analysis the 454 probe sets whose expression corre-
lates with NH, cell lines still tend to cluster according to the tissue of
origin (Figure W4). However, in this case, there is also a correlation
of the clustering pattern with NH (Supplementary Results).
To address this question of origin-independent transcriptional
changes associated with NH, we used two approaches. First, to esti-
mate possible biases imposed on karyotype correlations by tissue-of-
origin groupings, we used a “jackknife” procedure: each tissue-of-origin
was omitted in turn, and SCCs for the 454 probe sets that had SCCs
between NH and gene expression with P values ≤ .001 were calculated
for the excluded subset of cell lines. For all 454, 99% jackknife confi-
dence intervals of SCCs excluded zero and remained positive or nega-
tive throughout, confirming that correlation of the expression of these
transcripts with NH is not associated with any specific tissue-of-origin
(data not shown).
Second, univariate F test identifies 1579 and 1098 probe sets in
U133A and U133B arrays, respectively, as differentially expressed be-
tween cell lines grouped according to their 9 tissues of origin. Among
them, 241 array features (corresponding to 172 genes) overlap with
the previously identified ones significantly associated with NH (P <
.001). Consequently, among the 454 Affymetrix IDs associated with
NH at P < .001, 213 IDs corresponding to 188 genes are not dif-
ferentially expressed based on their tissue of origin (129 features/
121 genes negative, 84 features/67 genes positive; Table W3).
Discussion
Aneuploidy and chromosomal instability are common conditions
for most epithelial cancer cells, but the relationships between those
factors and cellular functions are not clear. We, therefore, used cor-
relations between NH and gene expression profiles of the NCI-60
cell lines, followed by Gene Ontology (GO) categorization, to iden-
tify genes and cellular processes associated with the increase of chro-
mosomal instability in cancer cells.
Gene Ontology analysis of the distribution of 360 genes correlated
with NH (P < .001) indicated that cell communication and signal
transduction, cell adhesion, motility, and migration, response to
wounding and inflammatory response, negative regulation of cell
proliferation, and DNA replication are the main biological processes
associated with numerical heterogeneity of the chromosomal con-
tent in the cancer cells (Table 2). Moreover, when these genes were
divided into two groups based on their positive or negative correla-
tion coefficients, we saw a striking difference between these two
groups. Genes, expression of which was positively correlated with
NH, fell into GO categories such as cell communication and signal
transduction, including cell surface receptor–linked signal transduc-
tion, cell adhesion, locomotion, motility, and migration, develop-
ment, morphogenesis, and differentiation, response to wounding,
and inflammatory response (Figure 1A). Products of these genes
were associated with extracellular matrix and extracellular space,
plasma membrane, and cytoskeleton and were involved in the focal
adhesion pathway (HSA04510), cytokine–cytokine receptor interac-
tion (HSA04060), regulation of actin cytoskeleton (HSA04810),
JAK-STAT signaling pathways (HSA04630), cell communication
(HSA01430), and ECM-receptor interaction pathways (HSA04512;
Table 2).
Genes whose expression negatively correlated with NH fell into
totally different GO categories: cellular metabolism, nucleic acid me-
tabolism, regulation of transcription, DNA replication, response to
DNA damage stimulus, DNA repair, chromosome organization
and biogenesis, DNA packaging, unwinding and replication initia-
tion, and base-excision repair (Figure 1B and Table 2). Products of
those genes serve as transcription regulators, involved in nucleic acid
binding, linked to ATP-ase activity, and associated with the cell cycle
regulation pathway (HSA04110). They localize on intracellular organ-
elles and are, for the most part, found in the nucleus, chromosome/
chromatin, or nuclear envelope.
Among the 454 Affy IDs associated with NH at P < .001, 213 of
them (corresponding to 188 genes) are not differentially expressed
based on their tissue of origin (see the Results section). When we
examined distribution of 188 genes across GO categories, genes
whose expression is negatively associated with NH (121 genes) again
were significantly enriched within such categories as intracellular
membrane–bound organelle, nuclear protein, nucleic acid, or protein
binding, regulation of transcription, DNA replication initiation, cell
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Table 1. Top 50 Genes with Expression Profiles Correlated Positively (A) or Negatively (B) with NH across the NCI-60 Panel of Cancer Cell Lines.
Affy ID Gene Symbol Gene Name ρ P
(A)
209946_at VEGFC Vascular endothelial growth factor C 0.5817 2.08e−06
218717_s_at LEPREL1 Leprecan-like 1 0.5763 2.72e−06
218088_s_at RRAGC Ras-related GTP binding C 0.5750 2.89e−06
204140_at TPST1 Tyrosylprotein sulfotransferase 1 0.5549 7.48e−06
226656_at CRTAP Cartilage-associated protein 0.5501 9.31e−06
235086_at THBS1 Thrombospondin 1 0.5460 1.12e−05
212464_s_at FN1 Fibronectin 1 0.5428 1.29e−05
220092_s_at ANTXR1 Hypothetical protein FLJ10601 0.5425 1.30e−05
201426_s_at VIM Vimentin 0.5377 1.61e−05
202859_x_at IL8 Interleukin 8 0.5349 1.82e−05
201172_x_at ATP6V0E ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit E 0.5341 1.88e−05
211719_x_at FN1 Fibronectin 1 0.5331 1.96e−05
210495_x_at FN1 Fibronectin 1 0.5330 1.97e−05
201828_x_at CXX1 CAAX BOX 1 0.5306 2.18e−05
201380_at CRTAP Cartilage-associated protein 0.5301 2.22e−05
237444_at Unknown 0.5288 2.36e−05
205743_at STAC SH3 and cysteine-rich domain 0.5265 2.60e−05
201105_at LGALS1 Lectin, galactoside-binding, soluble, 1 (galectin 1) 0.5257 2.67e−05
200096_s_at ATP6V0E ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit E 0.5257 2.68e−05
204214_s_at RAB32 RAB32, member ras oncogene family 0.5248 2.78e−05
200885_at RHOC Ras homolog gene family, member C 0.5242 2.85e−05
231907_at ABL2 V-abl Abelson murine leukemia viral oncogene homolog 2 (ARG, Abelson-related gene) 0.5225 3.05e−05
226955_at FLJ36748 Hypothetical protein FLJ36748 0.5195 3.46e−05
216442_x_at FN1 Fibronectin 1 0.5172 3.79e−05
212509_s_at MXRA7 FLJ46603 protein 0.5144 4.26e−05
222834_s_at GNG12 Guanine nucleotide binding protein (G protein), gamma 12 0.5130 4.50e−05
224560_at TIMP2 TIMP metallopeptidase inhibitor 2 0.5127 4.56e−05
211612_s_at IL13RA1 Interleukin 13 receptor, alpha 1 0.5114 4.80e−05
226939_at CPEB2 Cytoplasmic polyadenylation element binding protein 2 0.5110 4.88e−05
202378_s_at LEPROT Leptin receptor overlapping transcript 0.5107 4.93e−05
235072_s_at Unknown 0.5104 4.99e−05
209226_s_at TNPO1 Transportin 1 0.5086 5.36e−05
202733_at P4HA2 Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II 0.5083 5.43e−05
220407_s_at TGFB2 Transforming growth factor, beta 2 0.5074 5.62e−05
212294_at GNG12 Guanine nucleotide binding protein (G protein), gamma 12 0.5073 5.64e−05
202377_at LEPR Leptin receptor 0.5064 5.85e−05
209278_s_at TFPI2 Tissue factor pathway inhibitor 2 0.5056 6.02e−05
201887_at IL13RA1 Interleukin 13 receptor, alpha 1 0.5048 6.23e−05
209225_x_at TNPO1 Transportin 1 0.5047 6.23e−05
208924_at RNF11 Ring finger protein 11 0.5044 6.31e−05
212658_at LHFPL2 Lipoma HMGIC fusion partner-like 2 0.5044 6.31e−05
213696_s_at MED8 Mediator of RNA polymerase II transcription, subunit 8 homolog (yeast) 0.5043 6.33e−05
229465_s_at PTPRD Protein tyrosine phosphatase, receptor type, D 0.5043 6.34e−05
203262_s_at FAM50A Family with sequence similarity 50, member A 0.5037 6.48e−05
209013_x_at TRIO Triple functional domain (PTPRF interacting) 0.5034 6.56e−05
207657_x_at TNPO1 Transportin 1 0.5026 6.78e−05
231579_s_at TIMP2 TIMP metallopeptidase inhibitor 2 0.5013 7.12e−05
200998_s_at CKAP4 Cytoskeleton-associated protein 4 0.5009 7.22e−05
229307_at ANKRD28 Ankyrin repeat domain 28 0.5001 7.45e−05
226893_at ABL2 V-abl Abelson murine leukemia viral oncogene homolog 2 (ARG, Abelson-related gene) 0.5000 7.48e−05
(B)
226148_at BTBD15 BTB (POZ) domain containing 15 −0.6236 2.20e−07
212316_at NUP210 Nucleoporin 210 kDa −0.6040 6.56e−07
224784_at MLLT6 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 6 −0.5733 3.15e−06
200069_at SART3 Squamous cell carcinoma antigen recognized by T cells 3 −0.5686 3.94e−06
212315_s_at NUP210 Nucleoporin 210 kDa −0.5666 4.35e−06
226482_s_at F11R F11 receptor −0.5620 5.38e−06
206687_s_at PTPN6 Protein tyrosine phosphatase, non–receptor type 6 −0.5518 8.60e−06
213947_s_at NUP210 Nucleoporin 210 kDa −0.5473 1.06e−05
212482_at FLJ13910 Hypothetical protein FLJ13910 −0.5423 1.32e−05
227134_at SYTL1 Synaptotagmin-like 1 −0.5405 1.42e−05
204142_at ENOSF1 Enolase superfamily member 1 −0.5376 1.62e−05
224428_s_at CDCA7 Cell division cycle–associated 7 −0.5354 1.78e−05
201969_at NASP Nuclear autoantigenic sperm protein (histone-binding) −0.5354 1.78e−05
225887_at Chromosome 13 open reading frame 23 −0.5305 2.19e−05
218491_s_at THYN1 Thymocyte nuclear protein 1 −0.5300 2.24e−05
227560_at SFXN2 Sideroflexin 2 −0.5288 2.35e−05
204798_at MYB V-myb myeloblastosis viral oncogene homolog (avian) −0.5250 2.76e−05
212978_at LRRC8B Leucine-rich repeat containing 8 family, member B −0.5218 3.15e−05
212446_s_at LASS6 LAG1 longevity assurance homolog 6 (Saccharomyces cerevisiae) −0.5215 3.18e−05
202107_s_at MCM2 MCM2 minichromosome maintenance deficient 2, mitotin (S. cerevisiae) −0.5202 3.36e−05
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Affy ID Gene Symbol Gene Name ρ P
212873_at HMHA1 Histocompatibility (minor) HA-1 −0.5197 3.43e−05
227378_x_at MGC13114 Hypothetical protein MGC13114 −0.5192 3.49e−05
213149_at DLAT Dihydrolipoamide S -acetyltransferase (E2 component of pyruvate dehydrogenase complex) −0.5189 3.55e−05
227586_at LOC124491 LOC124491 −0.5188 3.55e−05
204767_s_at FEN1 Flap structure–specific endonuclease 1 −0.5170 3.83e−05
201038_s_at ANP32A Acidic (leucine-rich) nuclear phosphoprotein 32 family, member A −0.5166 3.90e−05
208901_s_at TOP1 Topoisomerase (DNA) I −0.5163 3.94e−05
219378_at NARG1L NMDA receptor–regulated 1–like −0.5155 4.07e−05
225179_at HIP2 Huntingtin interacting protein 2 −0.5151 4.13e−05
225716_at BRI3BP BRI3 binding protein −0.5139 4.34e−05
217980_s_at MRPL16 Mitochondrial ribosomal protein L16 −0.5125 4.59e−05
225845_at BTBD15 BTB (POZ) domain containing 15 −0.5116 4.75e−05
213251_at LOC441046 Hypothetical LOC 441046 −0.5101 5.04e−05
220035_at NUP210 Nucleoporin 210 kDa −0.5091 5.26e−05
223268_at C11ORF54 Chromosome 11 open reading frame 54 −0.5091 5.26e−05
210206_s_at DDX11 Dead/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like helicase homolog, S. cerevisiae) −0.5079 5.52e−05
202778_s_at ZNF198 Zinc finger protein 198 −0.5058 5.99e−05
201202_at PCNA Proliferating cell nuclear antigen −0.5053 6.09e−05
212943_at KIAA0528 KIAA0528 −0.5048 6.21e−05
219067_s_at C10ORF86 Chromosome 10 open reading frame 86 −0.5044 6.31e−05
219188_s_at LRP16 LRP16 protein −0.5020 6.94e−05
201401_s_at ADRBK1 Adrenergic, beta, receptor kinase 1 −0.5014 7.10e−05
203375_s_at TPP2 Tripeptidyl peptidase II −0.4994 7.65e−05
200091_s_at RPS25 Ribosomal protein S25 −0.4992 7.72e−05
224944_at TMPO Thymopoietin −0.4982 8.01e−05
228992_at MED28 Mediator of RNA polymerase II transcription, subunit 28 homolog (yeast) −0.4970 8.39e−05
213626_at CBR4 Carbonic reductase 4 −0.4966 8.54e−05
231887_s_at KIAA1274 KIAA1274 −0.4926 9.91e−05
202163_s_at CNOT8 CCR4-NOT transcription complex, subunit 8 −0.4906 1.07e−04
202163_s_at CNOT8 CCR4-NOT transcription complex, subunit 8 −0.4906 1.07e−04
Table 1. (continued )
Table 2. Gene Ontology Categories Associated with Genes Whose Expression Profiles Correlated with NH (P < .001) Across the NCI-60 Panel of Cancer Cell Lines.
Category GO Term GO Terms Associated
with 360 Gene Transcripts
Correlated with NH,
P < .001
GO Terms Associated
with 189 Gene Transcripts
Positively Correlated with
NH, P < .001
GO Terms Associated
with 171 Gene Transcripts
Negatively Correlated with
NH, P < .001
Count % P Count % P Count % P
GOTERM_BP_ALL homophilic cell adhesion 22 5.76 1.14e−13 22 10.48 9.44e−19
GOTERM_BP_ALL cell-cell adhesion 23 6.02 4.25e−11 23 10.95 3.08e−16
GOTERM_BP_ALL cell adhesion 36 9.69 1.16e−08 36 17.14 2.35e−15
GOTERM_BP_ALL cell surface receptor–linked signal transduction 32 8.38 9.20e−04 27 12.86 3.65e−06
GOTERM_BP_ALL cell communication 70 18.32 4.48e−02 54 25.71 8.16e−05
GOTERM_BP_ALL signal transduction 65 17.02 6.08e−02 50 23.81 2.30e−04
GOTERM_BP_ALL response to wounding 13 3.40 7.31e−03 11 5.24 9.33e−04
GOTERM_BP_ALL response to external stimulus 16 4.19 7.84e−03 13 6.19 1.11e−03
GOTERM_BP_ALL development 41 10.80 2.80e−01 36 17.14 1.14e−03
GOTERM_BP_ALL locomotion 15 3.93 1.39e−03 11 5.24 1.33e−03
GOTERM_BP_ALL localization of cell 15 3.93 1.39e−03 11 5.24 1.33e−03
GOTERM_BP_ALL cell motility 15 3.93 1.39e−03 11 5.24 1.33e−03
GOTERM_BP_ALL cell migration 8 2.09 1.20e−02 7 3.33 2.88e−03
GOTERM_BP_ALL G-protein–coupled receptor protein signaling pathway 14 3.66 3.38e−03 10 4.76 4.18e−03
GOTERM_BP_ALL inflammatory response 9 2.36 5.25e−03 7 3.33 4.26e−03
GOTERM_BP_ALL cellular morphogenesis 10 4.76 1.75e−02
GOTERM_BP_ALL cell differentiation 12 5.71 2.68e−02
GOTERM_BP_ALL response to other organism 13 3.40 8.48e−02 10 4.76 3.16e−02
GOTERM_BP_ALL neurogenesis 5 2.38 3.17e−02
GOTERM_BP_ALL acute-phase response 3 0.79 8.75e−02 3 1.43 3.18e−02
GOTERM_BP_ALL morphogenesis 15 3.90 4.70e−01 14 6.67 4.30e−02
GOTERM_BP_ALL negative regulation of cell proliferation 10 2.62 2.49e−02 6 2.86 9.36e−02
GOTERM_BP_ALL neutrophil chemotaxis 3 0.79 2.30e−02
GOTERM_BP_ALL regulation of chemotaxis 3 0.79 2.30e−02
GOTERM_BP_ALL positive regulation of chemotaxis 3 0.79 2.30e−02
GOTERM_BP_ALL immune cell migration 3 0.79 3.33e−02
GOTERM_BP_ALL immune cell chemotaxis 3 0.79 3.33e−02
GOTERM_CC_ALL membrane 108 28.42 5.18e−02 85 40.48 1.83e−06
GOTERM_CC_ALL intrinsic to membrane 78 20.53 7.70e−02 64 30.48 1.77e−05
GOTERM_CC_ALL plasma membrane 29 13.81 6.32e−03
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Table 2. (continued )
Category GO Term GO Terms Associated
with 360 Gene Transcripts
Correlated with NH,
P < .001
GO Terms Associated
with 189 Gene Transcripts
Positively Correlated with
NH, P < .001
GO Terms Associated
with 171 Gene Transcripts
Negatively Correlated with
NH, P < .001
Count % P Count % P Count % P
GOTERM_CC_ALL extracellular region 25 6.58 6.30e−03 25 11.90 1.75e−06
GOTERM_CC_ALL intrinsic to plasma membrane 20 9.52 1.24e−02
GOTERM_CC_ALL cytoskeleton 19 9.05 5.25e−02
GOTERM_CC_ALL extracellular matrix 10 2.63 4.36e−02 10 4.76 1.66e−03
GOTERM_CC_ALL extracellular space 8 3.81 3.35e−02
GOTERM_CC_ALL heterotrimeric G-protein complex 3 1.43 4.23e−02
GOTERM_CC_ALL extrinsic to plasma membrane 4 1.05 2.63e−02 3 1.43 5.77e−02
GOTERM_MF_ALL calcium ion binding 35 9.21 6.86e−06 35 16.67 8.96e−13
GOTERM_MF_ALL metal ion binding 66 31.43 2.57e−06
GOTERM_MF_ALL cation binding 59 28.10 1.48e−05
GOTERM_MF_ALL transmembrane receptor activity 16 4.21 2.62e−02 16 7.62 7.32e−05
GOTERM_MF_ALL signal transducer activity 39 18.57 1.52e−04
GOTERM_MF_ALL protein binding 135 35.53 3.29e−03 81 38.57 1.45e−03
GOTERM_MF_ALL receptor activity 22 10.48 2.28e−03
GOTERM_MF_ALL actin binding 12 3.16 6.81e−02 10 4.76 1.06e−02
GOTERM_MF_ALL growth factor binding 4 1.90 2.60e−02
GOTERM_MF_ALL carbohydrate binding 6 2.86 3.63e−02
GOTERM_MF_ALL L-ascorbic acid binding 3 1.43 4.02e−02
GOTERM_MF_ALL enzyme regulator activity 15 7.14 4.06e−02
GOTERM_MF_ALL cytoskeletal protein binding 11 5.24 4.17e−02
GOTERM_MF_ALL extracellular matrix structural constituent 4 1.90 4.64e−02
GOTERM_MF_ALL oncostatin-M receptor activity 2 0.53 9.61e−02 2 0.95 5.34e−02
KEGG_PATHWAY HSA04060: CYTOKINE–CYTOKINE RECEPTOR INTERACTION 10 2.63 2.17e−03 10 4.76 6.75e−05
KEGG_PATHWAY HSA04510: FOCAL ADHESION 12 3.16 3.43e−02 11 5.24 3.78e−03
KEGG_PATHWAY HSA04630: JAK-STAT SIGNALING PATHWAY 8 2.11 1.68e−02 7 3.33 6.57e−03
KEGG_PATHWAY HSA01430: CELL COMMUNICATION 6 1.58 4.99e−02 5 2.38 3.85e−02
KEGG_PATHWAY HSA04810: REGULATION OF ACTIN CYTOSKELETON 8 3.81 4.37e−02
KEGG_PATHWAY HSA04512: ECM-RECEPTOR INTERACTION 5 2.38 5.13e−02
GOTERM_BP_ALL DNA-dependent DNA replication 12 3.14 1.67e−04 12 7.02 3.70e−08
GOTERM_BP_ALL DNA replication 15 3.93 1.80e−03 15 8.77 1.08e−07
GOTERM_BP_ALL DNA replication initiation 7 1.83 1.74e−04 7 4.09 1.25e−06
GOTERM_BP_ALL nucleobase, nucleoside, nucleotide and nucleic acid metabolism 57 33.33 3.65e−06
GOTERM_BP_ALL DNA metabolism 22 12.87 1.09e−05
GOTERM_BP_ALL regulation of cellular metabolism 38 22.22 1.03e−04
GOTERM_BP_ALL regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism 36 21.05 1.21e−04
GOTERM_BP_ALL transcription 36 21.05 2.14e−04
GOTERM_BP_ALL regulation of transcription 34 19.88 3.73e−04
GOTERM_BP_ALL macromolecule metabolism 61 35.67 4.92e−03
GOTERM_BP_ALL cellular metabolism 85 49.71 5.44e−03
GOTERM_BP_ALL response to DNA damage stimulus 10 5.85 6.34e−03
GOTERM_BP_ALL response to endogenous stimulus 10 5.85 7.73e−03
GOTERM_BP_ALL cell cycle 24 N/A N/A 18 10.53 8.62e−03
GOTERM_BP_ALL DNA unwinding during replication 3 0.79 4.51e−02 3 1.75 8.85e−03
GOTERM_BP_ALL DNA repair 9 5.26 9.74e−03
GOTERM_BP_ALL DNA packaging 7 4.09 3.44e−02
GOTERM_BP_ALL phosphoinositide-mediated signaling 4 2.34 3.78e−02
GOTERM_BP_ALL base-excision repair 3 1.75 3.96e−02
GOTERM_BP_ALL chromosome organization and biogenesis 8 4.68 4.19e−02
GOTERM_BP_ALL DNA ligation during DNA repair 2 0.52 9.85e−02 2 1.17 4.23e−02
GOTERM_BP_ALL base-excision repair, DNA ligation 2 0.52 9.85e−02 2 1.17 4.23e−02
GOTERM_CC_ALL nucleus 71 41.52 6.28e−10
GOTERM_CC_ALL intracellular organelle 92 53.80 2.32e−07
GOTERM_CC_ALL organelle 92 53.80 2.37e−07
GOTERM_CC_ALL intracellular membrane-bound organelle 85 49.71 4.34e−07
GOTERM_CC_ALL intracellular 100 58.48 1.88e−06
GOTERM_CC_ALL chromosome 15 3.68 4.65e−02 15 8.77 2.62e−06
GOTERM_CC_ALL chromatin 8 4.68 4.68e−04
GOTERM_CC_ALL intracellular non–membrane-bound organelle 25 14.62 1.11e−02
GOTERM_CC_ALL synaptic vesicle 3 1.75 2.53e−02
GOTERM_CC_ALL nuclear envelope 5 2.92 3.50e−02
GOTERM_CC_ALL condensed chromosome 3 1.75 4.36e−02
GOTERM_MF_ALL nucleic acid binding 55 32.16 4.48e−06
GOTERM_MF_ALL DNA binding 37 21.64 7.16e−05
GOTERM_MF_ALL DNA-dependent ATPase activity 6 1.32 2.09e−02 6 3.51 9.65e−05
GOTERM_MF_ALL RNA binding 16 9.36 9.44e−03
GOTERM_MF_ALL transcription regulator activity 22 12.87 9.78e−03
GOTERM_MF_ALL ATPase activity 9 5.26 2.13e−02
GOTERM_MF_ALL ATPase activity, coupled 8 4.68 3.19e−02
KEGG_PATHWAY HSA04110: CELL CYCLE 10 2.63 3.13e−02 10 5.85 1.64e−05
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cycle, chromatin-related protein, and DNA repair. Genes whose ex-
pression correlated positively with NH (67 genes) again showed sig-
nificant enrichment in such categories as cell communication and
signal transduction, extracellular region, development and morpho-
genesis, response to wounding, cell migration, and motility. In sum-
mary, then, the GO classifications of genes positively and negatively
associated with NH did not seem to depend on tissue of origin of the
cancer cell.
Evaluation of 1122 genes whose expression correlated with NH at
P < .01 (Table W4) revealed further enrichment of the same GO
categories identified under stricter conditions (P < .001; data shown
in the Table 2). That observation suggests that the essential findings
are not sensitive to the P value cutoff used. Also reassuring with re-
spect to robustness of the findings, analysis of the HG-U95A data
showed similar GO category enrichments (data not shown).
Focusing on the negative correlations of expression with NH, we
found enrichment of the following biological processes:
1) Cellular metabolism
2) Nucleic acid metabolism
3) Regulation of transcription
4) DNA replication
5) Response to DNA damage stimulus
6) DNA repair
7) Chromosome organization and biogenesis
8) DNA replication initiation
9) DNA packaging
10) Cell cycle regulation
The CIN phenotype has been associated with very rare mutations
in the checkpoint genes [22–27] and with decreased protein levels of
mitotic checkpoint components [25,27,28]. Deletion in mice of one
allele of Mad2, Bub1, or Bub3 compromises the mitotic checkpoint,
yielding higher rates of chromosome missegregation [29–32]. In our
study, regulators of mitotic cell cycle checkpoint (MAD2 and BUB3),
as well as a component of APC/C (APC4), are found among the
genes whose expression is negatively correlated with NH. Correla-
tions do not imply causative relationships; however, it would not
be unreasonable to suggest that the decreased level of mitotic check-
point components could be the basis of mitotic checkpoint relaxation
Figure 1. Biological processes associated with expression of genes positively (A) and negatively (B) correlated with NH.
1228 Chromosomal Instability and Gene Expression Roschke et al. Neoplasia Vol. 10, No. 11, 2008
leading to increased gains and losses of chromosomes. This supports
already existing assumptions that a compromised mitotic check-
point leads to accelerated rates of chromosomal instability in cancer
cells [33].
The expression of genes involved in DNA damage checkpoints
(CHK1, CHK2, H2AX, RAD21, XRCC5, DDB1) and DNA re-
replication prevention (BCCIP, BRCA2, CDT1, MCM2-7, cyclin B2)
negatively correlates with NH as well. The expression levels of genes
involved in DNA packaging, chromosome condensation, and kineto-
chore formation (H3 histone, H1FX, H2AX, H2AZ, TOP1, RCC1,
RCC2, SMARCA5, RCBTB1, CENPC1, ZWINT ) are also relatively
down-regulated in cancer cells with higher level of chromosomal insta-
bility compared to cancer cells with a lower level of instability.
Compromised cell cycle checkpoints give cancer cells an advantage
in that they may be able to proliferate in a stressful environment with
uncompleted DNA repair, perhaps with some level of unfinished
chromatin condensation and/or individualization of chromatids,
and perhaps with defects of mitotic chromosome organization. As
a result, on-going gains and losses of chromosomes or their fragments
can occur while cells are proliferating. We also found that chromo-
somal instability is associated with less effective cellular metabolism,
DNA replication and transcription, DNA repair and packaging,
weakness in proper chromatin condensation, and mitotic chromo-
some structural organization possibly owing to extensive imbalances
in cellular protein composition of cells that undergo continuous gains
and losses of parts of genome.
Gene Ontology’s biological processes positively correlated with
higher NH include the following:
1) Cell communication and signal transduction
2) Cell adhesion, including cell-cell adhesion
3) Cell surface receptor–linked signal transduction
4) Development and differentiation
5) Cell motility and migration
6) Response to wounding
7) Inflammatory response
8) G-protein–coupled receptor protein signaling
9) Cellular morphogenesis
A collective molecular portrait of numerical chromosomal het-
erogeneity in cancer cells includes relative up-regulation of genes
that are associated with increased motility and migration, epithelial-
mesenchymal transition (EMT), and are critical for tumor invasion
and metastasis: RhoC, fibronectin, LOX, TWIST, SNAI2, EGFR,
laminins, integrins, collagens, CDC42 effector protein (Rho GTPase
binding), Rho family GTPase 3, RAB, CXCL2, TGF-b2, VEGFC, IL-6,
IL-8, CTGF, vimentin, N-cadherin, CD44, BCAR3, protocadherins,
MMP2 and MMP14, NOTCH2, SERPINE1, 2, and 8, IGFBP3 and
7, TNFAIP3, TNFRSF12A and 19, PLAUR, and SPARC. Expression
of several genes that promote cell proliferation and G1 entry into cell
cycle (CCD1, EGFR, VEGFC ) correlate positively with the higher
NH as well.
Advances in the molecular profiling of cancer using genome-wide
approaches have revealed genes whose expression levels in primary
tumors correlate strongly with the likelihood of metastatic recurrence
[34–37]. In particular, genes that are involved in physiological pro-
grams of cellular response to tissue damage (inflammation, wound
healing, tissue remodeling, and regeneration) and genes that partici-
pate in differentiation and morphogenesis during epithelial tissue
development are involved in tumor invasiveness and metastasis
[38–41]. Important to those processes is an EMT, which enables
cells to undergo major changes in morphology, lose cellular con-
tacts, and acquire motility and ability to migrate. Also an important
part of those programs is stimulation of proliferation and differ-
entiation of epithelial cells themselves, as well as angiogenesis and
lymphangiogenesis. Our findings suggest a link, at least indirectly,
between chromosomal instability and cancer proliferation, invasion,
and metastasis.
Chromosomal instability can create both advantages and disadvan-
tages for cancer cells. For instance, severe genomic damage due to
losses or gains of whole chromosomes or their essential fragments
can prevent cancer cells from further proliferation. At the same time,
the program of response to tissue damage represents an advantageous
feature for overall cancer progression. Release of chemokines and
cytokines promotes a response from surrounding tumor and stromal
cells leading to the EMT in cancer cells, changes in cell adhesion
and motility, promoting epithelial cell proliferation, as well as angio-
genesis and lymphangiogenesis. We suggest that gross instability of
cancer cell genomes leads to evolution of cancer cell populations,
which “internalize” various inducers of a tissue damage response,
gradually making cancer cells more and more independent of envi-
ronmental stimuli. These changes in the gene expression pattern per-
sist in cancer-derived cell lines.
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Supplement: Cluster Analysis
Materials and Methods
For cluster analysis, U133A and U133B array data were processed
separately as described (Materials and Methods, main text) with
modifications. First, robust multichip average–transformed data were
filtered to have expression measures higher than 64 at least in two
cell lines, which is the minimum number of cell lines in a group.
Two gene sets were selected: one for which the interquartile range
in expression values was higher than 0.5 on log2 scale (11,848 probe
sets) and the second for which the interquartile range in expression
values was higher than 1 on log2 scale (this left 1667 and 682 probe
sets for U133A and U133B array data sets, respectively). Gene ex-
pression matrixes were then additionally normalized by subtracting
log2(median) expression value for each probe set. Gene expression
matrixes for differentially expressed genes selected according to the
F test (Materials and Methods, main text) and for 454 probe sets
that show correlation with numerical heterogeneity (NH) level were
also normalized by subtracting log2(median) expression value for
each probe set. This normalization makes results more comparable
when different distance measures are used. For Figures W2 to W4,
clustering was done by Hierarchical Ordered Partitioning And Col-
lapsing Hybrid (HOPACH) method as implemented in R package
hopach [1] using cosine angle (uncentered correlation) and Euclidean
distances for genes and arrays, respectively. For Figure W1, hierarchi-
cal clustering was performed by using function hclust (R package clus-
ter), Euclidean distance, and average linkage. In the HOPACH
algorithm, minimization of the median split silhouette value is used
to choose the cluster number and cluster ordering. Compared with
other clustering algorithms, the HOPACH method produces consis-
tent cluster ordering regardless of the original ordering of the arrays
in gene expression matrix [2]. Bootstrap resampling was done by se-
lecting 10,000 sets of 57 arrays one array at a time with replacement.
The proportion of resampled data sets in which each cell line falls
into each of the clusters serves as an estimate of the membership of
that cell line in each cluster. Bigger proportion of cell lines with con-
sistent membership in a cluster indicates that cluster is well differen-
tiated from other clusters and stable. Because we wanted to analyze
mainly cell line characteristics (particularly karyotypic instability),
the results are presented as ordered distance matrixes for cell lines
together with bar plots of the bootstrap reappearance proportions
for each cell line and each cluster. Additional details and results of
cluster analysis are available on request.
Results
Hierarchical clustering of the 57 cell lines from NCI-60 collection
shows that cell lines are mostly grouped according to the presumptive
tissue of origin when using 11,848 probe sets with moderate level in
expression variability (Figure W1).
We observed such correspondence after using for hierarchical
clustering of cell lines 2349 genes that were selected also nonspe-
cifically as displaying a higher (more than twofold difference between
25th and 75th percentiles) level of expression variability across cell
lines (Figure W2). However, it can be seen that there are some
similarities between cell lines unrelated to common tissue of ori-
gin: colon cell lines are similar to some prostate, renal, and ovar-
ian cell lines and some colon cell lines are also similar to leukemia
cell lines (Figure W2). Thus, though the tissue of origin seems to
be a critical factor that influences gene expression pattern in the
NCI-60 cell lines, there are additional variables that can be used
to stratify cell lines if the gene set is selected appropriately (see also
Ross et al. [3]).
For example, the correspondence of cell line gene expression pat-
terns to tissue of origin can be enhanced if clustering is performed
using a subset of genes that were selected according to an F test as
differentially expressed between cell lines of different tissues of origin
(Figure W3). Cell lines derived from leukemias, melanomas, colon
tumors, renal tumors, CNS tumors, and, to a lesser extent, lung tu-
mors form clusters that can be seen as separate blocks on the diagonal
of the ordered dissimilarity matrix. This confirms the results obtained
using spotted cDNA arrays [3] and illustrates that selection of genes
changes the cluster analysis results: the clusters defined by differen-
tially expressed genes are not only better separated but also are more
stable than clusters obtained using nonspecifically selected genes, as
follows from a bootstrap resampling analysis (compare Figures W2
and W3).
Impact of the tissue of origin of cell lines on gene expression pattern
can still be traced after clustering using 454 probe sets whose expres-
sion correlates with NH index. However, the ordered dissimilarity
matrix is quite different from the one based on genes differentially
expressed among cell lines of different tissues of origin (Figure W4).
Particularly, all cell lines derived from leukemia and colon tumors (to-
gether with two cell lines from breast tumors and one cell line from a
lung tumor) form a tight cluster that is remarkably stable upon boot-
strap resampling. Cell lines in this cluster have an average NH index of
0.27, whereas 21 cell lines in the biggest cluster that show maximal
dissimilarity (denoted by the presence of a white color in the matrix)
with the cluster of leukemia and colon cell lines have an average NH
index 0.65.
Clustering analysis demonstrates that gene expression is influenced
mainly by the tissue of origin, and at the same time, clustering of
genes selected based on their correlation with NH is different, dem-
onstrating an influence by NH as well.
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Table W2. List of 454 Array Features and Names of Corresponding Genes with Expression Profiles Correlated with NH (P < .001) Across the NCI-60 Panel of Cancer Cell Lines.
Affy ID Gene Symbol Description ρ P
226148_at BTBD15 BTB (POZ) domain containing 15 −0.6236 2.20e−07
212316_at NUP210 nucleoporin 210 kDa −0.6040 6.56e−07
209946_at VEGFC vascular endothelial growth factor C 0.5817 2.08e−06
218717_s_at LEPREL1 leprecan-like 1 0.5763 2.72e−06
218088_s_at RRAGC Ras-related GTP binding C 0.5750 2.89e−06
224784_at MLLT6 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 6 −0.5733 3.15e−06
200069_at SART3 squamous cell carcinoma antigen recognized by T cells 3 −0.5686 3.94e−06
212315_s_at NUP210 nucleoporin 210 kDa −0.5666 4.35e−06
226482_s_at F11R F11 receptor −0.5620 5.38e−06
204140_at TPST1 tyrosylprotein sulfotransferase 1 0.5549 7.48e−06
206687_s_at PTPN6 protein tyrosine phosphatase, non–receptor type 6 −0.5518 8.60e−06
226656_at CRTAP cartilage associated protein 0.5501 9.31e−06
213947_s_at NUP210 nucleoporin 210 kDa −0.5473 1.06e−05
235086_at THBS1 Thrombospondin 1 0.5460 1.12e−05
212464_s_at FN1 fibronectin 1 0.5428 1.29e−05
220092_s_at ANTXR1 anthrax toxin receptor 1 0.5425 1.30e−05
212482_at RMND5A hypothetical protein FLJ13910 −0.5423 1.32e−05
227134_at SYTL1 synaptotagmin-like 1 −0.5405 1.42e−05
201426_s_at VIM vimentin 0.5377 1.61e−05
204142_at ENOSF1 enolase superfamily member 1 −0.5376 1.62e−05
224428_s_at CDCA7 cell division cycle–associated 7 −0.5354 1.78e−05
201969_at NASP nuclear autoantigenic sperm protein (histone-binding) −0.5354 1.78e−05
202859_x_at IL8 interleukin 8 0.5349 1.82e−05
201172_x_at ATP6V0E1 ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit e 0.5341 1.88e−05
211719_x_at FN1 fibronectin 1 0.5331 1.96e−05
210495_x_at FN1 fibronectin 1 0.5330 1.97e−05
201828_x_at CAAX box 1 0.5306 2.18e−05
225887_at C13orf23 chromosome 13 open reading frame 23 −0.5305 2.19e−05
201380_at CRTAP cartilage-associated protein 0.5301 2.22e−05
218491_s_at THYN1 thymocyte protein Thy28 −0.5300 2.24e−05
227560_at SFXN2 sideroflexin 2 −0.5288 2.35e−05
237444_at Transcribed locus 0.5288 2.36e−05
205743_at STAC SH3 and cysteine–rich domain 0.5265 2.60e−05
201105_at LGALS1 lectin, galactoside-binding, soluble, 1 (galectin 1) 0.5257 2.67e−05
200096_s_at ATP6V0E ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit e 0.5257 2.68e−05
204798_at MYB v-myb myeloblastosis viral oncogene homolog (avian) −0.5250 2.76e−05
204214_s_at RAB32 RAB32, member RAS oncogene family 0.5248 2.78e−05
200885_at RHOC ras homolog gene family, member C 0.5242 2.85e−05
231907_at ABL2 V-abl Abelson murine leukemia viral oncogene homolog 2 (ARG, Abelson-related gene) 0.5225 3.05e−05
212978_at LRRC8B Leucine-rich repeat containing 8 family, member B −0.5218 3.15e−05
212446_s_at LASS6 LAG1 longevity assurance homolog 6 (S. cerevisiae) −0.5215 3.18e−05
Table W1. Number of Gene Expression Array Elements and Corresponding Genes Correlated
with Structural Complexity, Structural Heterogeneity, Numerical Complexity, and Numerical
Heterogeneity with P < .01 and P < .001.
P < .01 P < .001
Array Elements Genes Array Elements Genes
SC-positive 190 165 20 18
SC-negative 187 166 34 32
SC total 377 331 54 50
FP 0.95 279 38
FP 0.99 430 75
SH-positive 733 560 215 168
SH-negative 398 352 103 96
SH total 1131 912 318 264
FP 0.95 271 36
FP 0.99 446 82
NC-positive 568 419 148 106
NC-negative 479 407 130 118
NC total 1047 826 278 224
FP 0.95 306 44
FP 0.99 484 98
NH-positive 834 571 261 189
NH-negative 640 551 193 171
NH total 1474 1122 454 360
FP 0.95 290 43
FP 0.99 450 73
FP indicates false-positive results.
Affy ID Gene Symbol Description ρ P
202107_s_at MCM2 MCM2 minichromosome maintenance deficient 2, mitotin (S. cerevisiae) −0.5202 3.36e−05
212873_at HMHA1 minor histocompatibility antigen HA-1 −0.5197 3.43e−05
226955_at FLJ36748 hypothetical protein FLJ36748 0.5195 3.46e−05
227378_x_at MGC13114 hypothetical protein MGC13114 −0.5192 3.49e−05
213149_at DLAT dihydrolipoamide S -acetyltransferase (E2 component of pyruvate dehydrogenase complex) −0.5189 3.55e−05
227586_at LOC124491 LOC124491 −0.5188 3.55e−05
216442_x_at FN1 fibronectin 1 0.5172 3.79e−05
204767_s_at FEN1 flap structure-specific endonuclease 1 −0.5170 3.83e−05
201038_s_at ANP32A acidic (leucine-rich) nuclear phosphoprotein 32 family, member A −0.5166 3.90e−05
208901_s_at TOP1 topoisomerase (DNA) I −0.5163 3.94e−05
219378_at NARG1L NMDA receptor regulated 1–like −0.5155 4.07e−05
225179_at HIP2 Huntingtin interacting protein 2 −0.5151 4.13e−05
212509_s_at MXRA7 matrix-remodeling associated 7 0.5144 4.26e−05
225716_at full-length cDNA clone CS0DK008YI09 of HeLa cells Cot 25-normalized of Homo sapiens (human) −0.5139 4.34e−05
222834_s_at GNG12 guanine nucleotide binding protein (G protein), gamma 12 0.5130 4.50e−05
224560_at TIMP2 TIMP metallopeptidase inhibitor 2 0.5127 4.56e−05
217980_s_at MRPL16 mitochondrial ribosomal protein L16 −0.5125 4.59e−05
225845_at BTBD15 BTB (POZ) domain containing 15 −0.5116 4.75e−05
211612_s_at IL13RA1 interleukin 13 receptor, alpha 1 0.5114 4.80e−05
226939_at CPEB2 cytoplasmic polyadenylation element binding protein 2 0.5110 4.88e−05
202378_s_at LEPROT leptin receptor overlapping transcript 0.5107 4.93e−05
209153_s_at TCF3 transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47) −0.5104 4.99e−05
235072_s_at Transcribed locus 0.5104 4.99e−05
213251_at Hypothetical LOC 441046 −0.5101 5.04e−05
220035_at NUP210 nucleoporin 210 kDa −0.5091 5.26e−05
223268_at PTD012 PTD012 protein −0.5091 5.26e−05
209226_s_at TNPO1 transportin 1 0.5086 5.36e−05
202733_at P4HA2 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II 0.5083 5.43e−05
210206_s_at DDX11 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like helicase homolog, S. cerevisiae) −0.5079 5.52e−05
220407_s_at TGFB2 transforming growth factor, beta 2 0.5074 5.62e−05
212294_at GNG12 guanine nucleotide binding protein (G protein), gamma 12 0.5073 5.64e−05
202377_at LEPR; LEPROT leptin receptor; leptin receptor overlapping transcript 0.5064 5.85e−05
202778_s_at ZMYM2 zinc finger protein 198 −0.5058 5.99e−05
209278_s_at TFPI2 tissue factor pathway inhibitor 2 0.5056 6.02e−05
201202_at PCNA proliferating cell nuclear antigen −0.5053 6.09e−05
212943_at KIAA0528 KIAA0528 gene product −0.5048 6.21e−05
201887_at IL13RA1 interleukin 13 receptor, alpha 1 0.5048 6.23e−05
209225_x_at TNPO1 transportin 1 0.5047 6.23e−05
219067_s_at NSMCE4A chromosome 10 open reading frame 86 −0.5044 6.31e−05
208924_at RNF11 ring finger protein 11 0.5044 6.31e−05
212658_at LHFPL2 lipoma HMGIC fusion partner–like 2 0.5044 6.31e−05
213696_s_at MED8 mediator of RNA polymerase II transcription, subunit 8 homolog (yeast) 0.5043 6.33e−05
229465_s_at PTPRS protein tyrosine phosphatase, receptor type, S 0.5043 6.34e−05
203262_s_at FAM50A family with sequence similarity 50, member A 0.5037 6.48e−05
209013_x_at TRIO triple functional domain (PTPRF interacting) 0.5034 6.56e−05
207657_x_at TNPO1 transportin 1 0.5026 6.78e−05
219188_s_at LRP16 protein −0.5020 6.94e−05
201401_s_at ADRBK1 adrenergic, beta, receptor kinase 1 −0.5014 7.10e−05
231579_s_at TIMP2 TIMP metallopeptidase inhibitor 2 0.5013 7.12e−05
200998_s_at CKAP4 cytoskeleton-associated protein 4 0.5009 7.22e−05
229307_at ANKRD28 ankyrin repeat domain 28 0.5001 7.45e−05
226893_at ABL2 V-abl Abelson murine leukemia viral oncogene homolog 2 (ARG, Abelson-related gene) 0.5000 7.48e−05
224796_at DDEF1 development and differentiation enhancing factor 1 0.5000 7.49e−05
203375_s_at TPP2 tripeptidyl peptidase II −0.4994 7.65e−05
238447_at RBMS3 RNA binding motif, single-stranded interacting protein 0.4994 7.66e−05
200091_s_at RPS25 ribosomal protein S25 −0.4992 7.72e−05
224944_at TMPO Thymopoietin −0.4982 8.01e−05
228234_at TICAM2 toll-like receptor adaptor molecule 2 0.4974 8.27e−05
209019_s_at PINK1 PTEN-induced putative kinase 1 0.4974 8.28e−05
200757_s_at CALU calumenin 0.4973 8.29e−05
228992_at MED28 Mediator of RNA polymerase II transcription, subunit 28 homolog (yeast) −0.4970 8.39e−05
213626_at CBR4 carbonic reductase 4 −0.4966 8.54e−05
209263_x_at TSPAN4 tetraspanin 4 0.4964 8.61e−05
225765_at TNPO1 Transportin 1 0.4955 8.89e−05
203695_s_at DFNA5 deafness, autosomal dominant 5 0.4952 8.99e−05
212470_at SPAG9 sperm-associated antigen 9 0.4948 9.12e−05
213455_at hypothetical LOC283677 0.4947 9.16e−05
204359_at FLRT2 fibronectin leucine rich transmembrane protein 2 0.4945 9.25e−05
214696_at hypothetical protein MGC14376 0.4937 9.53e−05
231887_s_at KIAA1274 KIAA1274 −0.4926 9.91e−05
203773_x_at BLVRA biliverdin reductase A 0.4921 1.01055e−
200756_x_at CALU calumenin 0.4916 1.03041e−
209264_s_at TSPAN4 tetraspanin 4 0.4909 1.05831e−
Table W2. (continued )
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224790_at DDEF1 development and differentiation enhancing factor 1 0.4908 1.06088e−
202163_s_at CNOT8 CCR4-NOT transcription complex, subunit 8 −0.4906 1.07122e−
221771_s_at M-phase phosphoprotein, mpp8 −0.4903 1.08198e−
218458_at GMCL1 germ cell–less homolog 1 (Drosophila) −0.4900 1.09481e−
212973_at RPIA ribose 5-phosphate isomerase A (ribose 5-phosphate epimerase) −0.4900 1.09481e−
221737_at GNA12 guanine nucleotide binding protein (G protein) alpha 12 0.4896 1.10947e−
201976_s_at MYO10 myosin X 0.4896 1.10947e−
221753_at SSH1 slingshot homolog 1 (Drosophila) 0.4895 1.11215e−
212430_at RBM38 RNA-binding region (RNP1, RRM) containing 1 −0.4884 1.15975e−
200943_at HMGN1 high-mobility group nucleosome binding domain 1 −0.4884 1.16009e−
222514_at RRAGC Ras-related GTP binding C 0.4881 1.17272e−
233888_s_at SRGAP1 SLIT-ROBO Rho GTPase activating protein 1 0.4881 1.17555e−
223199_at MKNK2 MAP kinase interacting serine/threonine kinase 2 −0.4877 1.19155e−
200990_at TRIM28 tripartite motif-containing 28 −0.4871 1.21574e−
218980_at FHOD3 formin homology 2 domain containing 3 0.4871 1.21719e−
209832_s_at CDT1 DNA replication factor −0.4865 1.24670e−
227228_s_at KIAA1509 KIAA1509 −0.4863 1.25418e−
224504_s_at MGC13125 hypothetical protein MGC13125 −0.4862 1.25718e−
217785_s_at YKT6 SNARE protein Ykt6 0.4861 1.26170e−
212607_at AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) 0.4861 1.26321e−
200859_x_at FLNA filamin A, alpha (actin binding protein 280) 0.4860 1.26774e−
210053_at TAF5 TAF5 RNA polymerase II, TATA box binding protein (TBP)–associated factor, 100 kDa −0.4853 1.29954e−
224791_at DDEF1 development and differentiation enhancing factor 1 0.4848 1.32651e−
202555_s_at MYLK myosin, light polypeptide kinase 0.4845 1.34239e−
226651_at HOMER1 homer homolog 1 (Drosophila) −0.4844 1.34718e−
201885_s_at CYB5R3 cytochrome b5 reductase 3 0.4843 1.3520e−0
208549_x_at PTMA prothymosin, alpha (gene sequence 28); similar to prothymosin alpha; hypothetical gene supported
by BC013859; hypothetical gene supported by BC013859; BC070480
−0.4839 1.36815e−
223625_at DRCTNNB1A down-regulated by Ctnnb1, a 0.4838 1.37629e−
205083_at AOX1 aldehyde oxidase 1 0.4832 1.40764e−
204141_at TUBB2A tubulin, beta 2 0.4831 1.41265e−
202087_s_at CTSL1 cathepsin L 0.4825 1.44305e−
208838_at CAND1 cullin-associated and neddylation-dissociated 1 −0.4822 1.45847e−
224677_x_at C11orf31 chromosome 11 open reading frame 31 −0.4820 1.46756e−
206157_at PTX3 pentraxin-related gene, rapidly induced by IL-1 beta 0.4807 1.54150e−
209420_s_at SMPD1 sphingomyelin phosphodiesterase 1, acid lysosomal (acid sphingomyelinase) 0.4806 1.54512e−
211066_x_at PCDHG protocadherin gamma subfamily 0.4806 1.54694e−
213746_s_at FLNA filamin A, alpha (actin binding protein 280) 0.4802 1.56889e−
215501_s_at DUSP10 dual-specificity phosphatase 10 0.4797 1.59722e−
205717_x_at PCDHG protocadherin gamma subfamily 0.4796 1.59868e−
209012_at TRIO triple functional domain (PTPRF interacting) 0.4786 1.66008e−
209083_at CORO1A coronin, actin binding protein, 1A −0.4782 1.68691e−
204143_s_at ENOSF1 enolase superfamily member 1 −0.4778 1.70668e−
225878_at KIF1B kinesin family member 1B 0.4773 1.74079e−
224610_at full-length cDNA clone CL0BB014ZH04 of neuroblastoma of Homo sapiens (human) −0.4772 1.74688e−
201930_at MCM6 MCM6 minichromosome maintenance deficient 6 (MIS5 homolog, Schizosaccharomyces pombe)
(S. cerevisiae)
−0.4768 1.76935e−
201110_s_at THBS1 thrombospondin 1 0.4755 1.85546e−
226099_at ELL2 elongation factor, RNA polymerase II, 2 0.4749 1.89665e−
210547_x_at ICA1 islet cell autoantigen 1, 69 kDa −0.4746 1.91645e−
201051_at ANP32A acidic (leucine-rich) nuclear phosphoprotein 32 family, member A −0.4744 1.93198e−
201185_at HTRA1 HtrA serine peptidase 1 0.4742 1.94315e−
224663_s_at CFL2 cofilin 2 (muscle) 0.4735 1.99526e−
217843_s_at MED4 mediator of RNA polymerase II transcription, subunit 4 homolog (yeast) −0.4724 2.06753e−
224823_at MYLK myosin, light polypeptide kinase 0.4722 2.08417e−
222036_s_at MCM4 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae) −0.4720 2.10334e−
214752_x_at FLNA filamin A, alpha (actin binding protein 280) 0.4719 2.11121e−
200668_s_at UBE2D3 ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) −0.4718 2.11299e−
205207_at IL6 interleukin 6 (interferon, beta 2) 0.4717 2.12268e−
211160_x_at ACTN1 actinin, alpha 1 0.4713 2.15198e−
222880_at AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) 0.4707 2.19914e−
229067_at similar to Formin binding protein 2 (srGAP2) 0.4702 2.23957e−
218420_s_at C13orf23 chromosome 13 open reading frame 23 −0.4697 2.27551e−
226574_at PSPC1; LOC374491 paraspeckle component 1; TPTE and PTEN homologous inositol lipid phosphatase pseudogene −0.4697 2.27551e−
221563_at DUSP10 dual-specificity phosphatase 10 0.4690 .0002335
224773_at NAV1 neuron navigator 1 0.4688 2.34631e−
202074_s_at OPTN optineurin 0.4686 2.3650e−0
211981_at COL4A1 collagen, type IV, alpha 1 0.4682 2.40005e−
202830_s_at SLC37A4 solute carrier family 37 (glycerol-6-phosphate transporter), member 4 −0.4681 2.40548e−
200788_s_at PEA15 phosphoprotein enriched in astrocytes 15 0.4680 2.41912e−
205129_at NPM3 nucleophosmin/nucleoplasmin, 3 −0.4678 2.43558e−
221829_s_at TNPO1 transportin 1 0.4675 2.45842e−
233496_s_at CFL2 cofilin 2 (muscle) 0.4661 2.58543e−
Table W2. (continued )
Affy ID Gene Symbol Description ρ P
205130_at RAGE renal tumor antigen 0.4659 2.59708e−
209897_s_at SLIT2 slit homolog 2 (Drosophila) 0.4658 2.60584e−
217872_at PIH1D1 hypothetical protein FLJ20643 −0.4656 2.62935e−
225464_at FRMD6 FERM domain containing 6 0.4653 2.65007e−
225398_at RPUSD4 RNA pseudouridylate synthase domain containing 4 −0.4653 2.65304e−
225703_at KIAA1545 KIAA1545 protein −0.4653 2.65602e−
200663_at CD63 CD63 antigen (melanoma 1 antigen) 0.4650 2.68074e−
235706_at CPM carboxypeptidase M 0.4650 2.68294e−
208808_s_at HMGB2 high-mobility group box 2 −0.4648 2.6980e−0
220750_s_at LEPRE1 leucine-proline–enriched proteoglycan (leprecan) 1 0.4648 2.70102e−
226621_at OSMR oncostatin M receptor 0.4639 2.78689e−
200099_s_at RPS3A ribosomal protein S3A −0.4636 2.81501e−
204948_s_at FST follistatin transformer-2 alpha 0.4635 2.82529e−
204658_at −0.4627 2.89772e−
213069_at HEG1 HEG homolog 1 (zebrafish) 0.4625 2.92361e−
235570_at RBMS3 RNA binding motif, single-stranded interacting protein 0.4624 2.93337e−
235138_at PUM2 Pumilio homolog 2 (Drosophila) −0.4624 2.93663e−
235705_at 0.4621 2.96284e−
200073_s_at HNRPD heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37 kDa) −0.4621 2.96613e−
204425_at ARHGAP4 Rho GTPase activating protein 4 −0.4619 2.97933e−
221096_s_at TMCO6 hypothetical protein PRO1580 −0.4619 2.98263e−
214247_s_at DKK3 dickkopf homolog 3 (Xenopus laevis) 0.4619 2.98594e−
222222_s_at HOMER3 homer homolog 3 (Drosophila) 0.4615 3.01950e−
231045_x_at C11orf31 chromosome 11 open reading frame 31 −0.4614 3.02929e−
214212_x_at PLEKHC1 pleckstrin homology domain containing, family C (with FERM domain) member 1 0.4613 3.03937e−
217882_at TMEM111 30 kDa protein 0.4613 3.04274e−
216232_s_at GCN1L1 GCN1 general control of amino acid synthesis 1–like 1 (yeast) −0.4612 3.05286e−
226084_at MAP1B microtubule-associated protein 1B 0.4612 3.05625e−
226982_at ELL2 elongation factor, RNA polymerase II, 2 0.4611 3.05963e−
204032_at BCAR3 breast cancer anti–estrogen resistance 3 0.4611 3.06981e−
224694_at ANTXR1 anthrax toxin receptor 1 0.4608 3.10052e−
210416_s_at CHEK2 CHK2 checkpoint homolog (S. pombe) −0.4605 3.13244e−
202052_s_at RAI14 retinoic acid–induced 14 0.4601 3.16977e−
229663_at LONPL peroxisomal LON protease like 0.4600 3.17677e−
208637_x_at ACTN1 actinin, alpha 1 0.4597 3.21908e−
212457_at TFE3 transcription factor binding to IGHM enhancer 3 0.4596 3.22618e−
226697_at LOC92689 hypothetical protein BC001096 0.4595 3.23329e−
200755_s_at CALU calumenin 0.4591 3.27629e−
225146_at C9orf25 chromosome 9 open reading frame 25 0.4588 3.31615e−
213713_s_at hypothetical protein BC008326 −0.4587 .0003327
213052_at PRKAR2A protein kinase, cAMP-dependent, regulatory, type II, alpha 0.4587 3.33076e−
201471_s_at SQSTM1 sequestosome 1 0.4585 3.34542e−
208973_at PRNPIP prion protein interacting protein 0.4585 3.34910e−
204009_s_at KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog −0.4582 3.38605e−
223206_s_at HSCARG HSCARG protein −0.4581 3.39721e−
224774_s_at NAV1 neuron navigator 1 0.4580 3.40094e−
218848_at THOC6 WD repeat domain 58 −0.4580 3.40840e−
200772_x_at PTMA prothymosin, alpha (gene sequence 28) −0.4579 3.41877e−
218448_at C20orf11 chromosome 20 open reading frame 11 −0.4573 3.48387e−
212330_at TFDP1 transcription factor Dp-1 −0.4570 3.51833e−
235308_at ZBTB20 zinc finger and BTB domain containing 20 0.4570 3.52603e−
211729_x_at BLVRA biliverdin reductase A 0.4569 3.53761e−
200047_s_at YY1 YY1 transcription factor −0.4566 3.56971e−
211921_x_at PTMA prothymosin, alpha (gene sequence 28) −0.4562 3.61173e−
201108_s_at THBS1 thrombospondin 1 0.4559 3.65131e−
224416_s_at MED28 mediator of RNA polymerase II transcription, subunit 28 homolog (yeast) −0.4558 3.66725e−
232816_s_at DDX11 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like helicase homolog, S. cerevisiae) −0.4554 3.71858e−
214150_x_at ATP6V0E1 ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit e 0.4553 3.72760e−
218407_x_at NENF neuron-derived neurotrophic factor 0.4545 3.82509e−
226777_at ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 0.4545 3.83018e−
221641_s_at ACOT9 acyl-CoA thioesterase 9 0.4539 3.90986e−
214845_s_at CALU calumenin 0.4537 3.93959e−
208804_s_at SFRS6 splicing factor, arginine/serine–rich 6 −0.4530 4.02132e−
200753_x_at SFRS2 splicing factor, arginine/serine–rich 2 −0.4530 4.03002e−
225688_s_at PHLDB2 pleckstrin homology–like domain, family B, member 2 0.4529 4.04309e−
202330_s_at UNG uracil-DNA glycosylase −0.4529 4.04309e−
202164_s_at CNOT8 CCR4-NOT transcription complex, subunit 8 −0.4527 4.06934e−
204490_s_at CD44 CD44 antigen (homing function and Indian blood group system) 0.4526 4.07374e−
224840_at FKBP5 FK506 binding protein 5 −0.4525 4.09697e−
223245_at STRBP spermatid perinuclear RNA binding protein −0.4525 4.10017e−
208896_at DDX18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 −0.4523 4.11789e−
204768_s_at FEN1 flap structure-specific endonuclease 1 −0.4521 4.15352e−
212593_s_at PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) −0.4515 4.22562e−
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215446_s_at LOX lysyl oxidase 0.4514 4.24383e−
203167_at TIMP2 TIMP metallopeptidase inhibitor 2 0.4512 4.27126e−
212419_at C10orf56 chromosome 10 open reading frame 56 0.4512 4.27585e−
227771_at LIFR leukemia inhibitory factor receptor 0.4511 4.28504e−
214257_s_at SEC22B SEC22 vesicle trafficking protein–like 1 (S. cerevisiae) 0.4510 4.30348e−
225798_at JAZF1 juxtaposed with another zinc finger gene 1 0.4509 4.31735e−
218069_at XTP3-transactivated protein A −0.4504 4.39203e−
221881_s_at CLIC4 chloride intracellular channel 4 0.4499 4.45834e−
202303_x_at SMARCA5 SWI/SNF–related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 5 −0.4496 4.50625e−
201493_s_at PUM2 pumilio homolog 2 (Drosophila) −0.4495 4.52072e−
213610_s_at KLHL23 kelch-like 23 (Drosophila) −0.4494 4.54007e−
226751_at C2orf32 chromosome 2 open reading frame 32 0.4493 4.54978e−
209079_x_at PCDHG protocadherin gamma subfamily 0.4491 4.57900e−
219944_at CLIP4 restin-like 2 0.4491 4.58389e−
227740_at UHMK1 U2AF homology motif (UHM) kinase 1 0.4489 4.61332e−
212195_at IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor) 0.4488 4.62316e−
201376_s_at HNRPF heterogeneous nuclear ribonucleoprotein F −0.4488 4.63303e−
210139_s_at PMP22 peripheral myelin protein 22 0.4488 4.63303e−
201559_s_at CLIC4 chloride intracellular channel 4 0.4486 4.65282e−
218067_s_at hypothetical protein FLJ10154 −0.4485 4.66771e−
208682_s_at MAGED2 melanoma antigen family D, 2 0.4484 4.68763e−
57163_at ELOVL1 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)–like 1 0.4483 4.70262e−
225563_at PAN3 PABP1-dependent poly A–specific ribonuclease subunit PAN3 −0.4483 4.70262e−
202391_at BASP1 brain-abundant, membrane-attached signal protein 1 0.4480 4.75291e−
200956_s_at SSRP1 structure-specific recognition protein 1 −0.4479 4.76303e−
213329_at SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 0.4476 4.80369e−
210371_s_at RBBP4 retinoblastoma binding protein 4 −0.4475 4.82414e−
209754_s_at TMPO thymopoietin −0.4475 4.83439e−
225391_at LOC93622 hypothetical protein BC006130 −0.4474 4.84981e−
217784_at YKT6 SNARE protein Ykt6 0.4471 4.89633e−
44702_at SYDE1 synapse defective 1, Rho GTPase, homolog 1 (Caenorhabditis elegans) 0.4466 4.97476e−
216262_s_at TGIF2 TGFB-induced factor 2 (TALE family homeobox) −0.4466 4.97476e−
202259_s_at phosphonoformate immunoassociated protein 5 −0.4465 4.98003e−
205909_at POLE2 polymerase (DNA-directed), epsilon 2 (p59 subunit) −0.4465 4.98531e−
204819_at FGD1 FYVE, RhoGEF and PH domain containing 1 (faciogenital dysplasia) 0.4464 4.99587e−
225381_at LOC399959 hypothetical gene supported by BX647608 0.4463 5.02768e−
218298_s_at C14orf159 chromosome 14 open reading frame 159 −0.4462 5.03833e−
215836_s_at PCDHG protocadherin gamma subfamily 0.4461 5.04899e−
209750_at NR1D2 nuclear receptor subfamily 1, group D, member 2 0.4459 5.08111e−
201035_s_at HADH L-3-hydroxyacyl–Coenzyme A dehydrogenase, short chain −0.4458 5.10802e−
226342_at SPTBN1 Spectrin, beta, non–erythrocytic 1 0.4458 5.10802e−
226934_at CPSF6 Cleavage and polyadenylation specific factor 6, 68 kDa −0.4449 5.25556e−
231810_at BRI3BP BRI3 binding protein −0.4445 5.31677e−
219779_at ZFHX4 zinc finger homeodomain 4 0.4443 5.36169e−
210904_s_at IL13RA1 interleukin 13 receptor, alpha 1 0.4442 5.36733e−
202258_s_at phosphonoformate-immunoassociated protein 5 −0.4441 5.38994e−
226912_at ZDHHC23 zinc finger, DHHC-type containing 23 −0.4438 5.43542e−
218168_s_at CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) −0.4436 5.48125e−
203632_s_at GPRC5B G protein–coupled receptor, family C, group 5, member B 0.4435 5.49852e−
241879_at Transcribed locus 0.4435 5.50429e−
200041_s_at BAT1 HLA-B–associated transcript 1 −0.4437 5.53484e−
228174_at GOLGA1 Golgi autoantigen, golgin subfamily a, 1 −0.4428 5.62083e−
219520_s_at WWC3 KIAA1280 protein 0.4428 5.62083e−
228121_at TGFB2 Transforming growth factor, beta 2 0.4423 5.70970e−
200957_s_at SSRP1 structure-specific recognition protein 1 −0.4422 5.72763e−
201616_s_at CALD1 caldesmon 1 0.4421 5.75762e−
232113_at Hypothetical gene supported by BX647608 0.4421 5.75762e−
217828_at SLTM modulator of estrogen induced transcription −0.4420 5.76363e−
219557_s_at NRIP3 nuclear receptor interacting protein 3 0.4418 5.79984e−
223711_s_at THY28 thymocyte protein Thy28 −0.4415 5.86065e−
218656_s_at LHFP lipoma HMGIC fusion partner 0.4415 5.87153e−
230130_at Transcribed locus 0.4414 5.88513e−
212709_at NUP160 nucleoporin 160 kDa −0.4411 5.94056e−
202125_s_at TRAK2 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 3 0.4410 5.95294e−
200679_x_at HMGB1 high-mobility group box 1 −0.4409 5.98399e−
227484_at CDNA FLJ41690 fis, clone HCASM2009405 0.4405 6.04654e−
222204_s_at RRN3 RRN3 RNA polymerase I transcription factor homolog (yeast) −0.4403 6.08436e−
214882_s_at SFRS2 splicing factor, arginine/serine–rich 2 −0.4403 6.08436e−
213836_s_at WIPI1 WD40 repeat protein interacting with phosphoinositides of 49 kDa 0.4401 6.12874e−
208178_x_at TRIO triple functional domain (PTPRF interacting) 0.4401 6.14008e−
224856_at FKBP5 FK506 binding protein 5 −0.4401 6.14148e−
213238_at ATP10D ATPase, class V, type 10D 0.4399 6.17983e−
201450_s_at TIA1 TIA1 cytotoxic granule–associated RNA binding protein −0.4398 6.18624e−
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201712_s_at RANBP2 RAN binding protein 2 −0.4395 6.24281e−
200977_s_at TAX1BP1 Tax1 (human T-cell leukemia virus type I) binding protein 1 0.4393 6.28315e−
225685_at CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 0.4390 6.34196e−
213139_at SNAI2 snail homolog 2 (Drosophila) 0.4390 6.34196e−
202948_at IL1R1 interleukin 1 receptor, type I 0.4390 6.34853e−
203317_at PSD4 pleckstrin and Sec7 domain containing 4 −0.4387 6.40974e−
202238_s_at NNMT nicotinamide N -methyltransferase 0.4386 6.42778e−
208795_s_at MCM7 MCM7 minichromosome maintenance deficient 7 (S. cerevisiae) −0.4386 6.43443e−
233364_s_at Hypothetical gene supported by BX647608 0.4386 6.43443e−
201848_s_at BNIP3 BCL2/adenovirus E1B 19 kDa interacting protein 3 0.4384 6.48111e−
203231_s_at ATXN1 ataxin 1 0.4382 6.50793e−
212233_at MAP1B Microtubule-associated protein 1B; Homo sapiens, clone IMAGE:5535936, mRNA 0.4381 6.54159e−
208747_s_at C1S complement component 1, s subcomponent 0.4380 6.56186e−
200999_s_at CKAP4 cytoskeleton-associated protein 4 0.4379 6.57541e−
214109_at LRBA LPS-responsive vesicle trafficking, beach and anchor containing −0.4377 6.62302e−
213338_at TMEM158 Ras-induced senescence 1 0.4374 6.67782e−
224940_s_at PAPPA pregnancy-associated plasma protein A, pappalysin 1 0.4374 6.69158e−
207749_s_at PPP2R3A protein phosphatase 2 (formerly 2A), regulatory subunit B″, alpha 0.4372 6.72805e−
203856_at VRK1 vaccinia-related kinase 1 −0.4371 6.74689e−
212603_at MRPS31 mitochondrial ribosomal protein S31 −0.4368 6.80261e−
236533_at DDEF1 development and differentiation enhancing factor 1 0.4367 6.82909e−
212789_at NCAPD3 KIAA0056 protein −0.4366 6.85170e−
204647_at HOMER3 homer homolog 3 (Drosophila) 0.4366 6.85874e−
203276_at LMNB1 lamin B1 −0.4366 6.85874e−
201170_s_at BHLHB2 basic helix-loop-helix domain containing, class B, 2 0.4364 6.90112e−
202302_s_at RSRC2 similar to splicing factor, arginine/serine–rich 4 –0.4363 6.92239e–
212443_at NBEAL2 neurobeachin-like 2 −0.4362 6.94373e−
212418_at ELF1 E74-like factor 1 (ets domain transcription factor) −0.4361 6.95891e−
207949_s_at ICA1 islet cell autoantigen 1, 69 kDa −0.4360 6.99374e−
209421_at MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (Escherichia coli) −0.4359 7.00092e−
218443_s_at DAZAP1 DAZ-associated protein 1 −0.4359 7.00809e−
225273_at KIAA1280 KIAA1280 protein 0.4359 7.00809e−
203229_s_at CLK2 CDC-like kinase 2 −0.4356 7.0730e−0
213798_s_at CAP1 CAP, adenylate cyclase–associated protein 1 (yeast) 0.4356 7.07504e−
216969_s_at KIF22 kinesin family member 22 −0.4355 7.10202e−
204489_s_at CD44 CD44 antigen (homing function and Indian blood group system) 0.4354 7.10929e−
208908_s_at CAST calpastatin 0.4353 7.13844e−
225481_at FRMD6 FERM domain containing 6 0.4351 7.18237e−
203388_at ARRB2 arrestin, beta 2 −0.4351 7.19707e−
212014_x_at CD44 CD44 antigen (homing function and Indian blood group system) 0.4348 7.26355e−
218295_s_at NUP50 nucleoporin 50 kDa −0.4344 7.34556e−
214663_at RIPK5 receptor interacting protein kinase 5 0.4343 7.36056e−
200770_s_at LAMC1 laminin, gamma 1 (formerly LAMB2) 0.4343 7.36807e−
218714_at PRR14 hypothetical protein MGC3121 −0.4342 7.39818e−
212822_at HEG1 HEG homolog 1 (zebrafish) 0.4340 7.44950e−
212920_at −0.4338 7.49516e−
217892_s_at LIMA1 epithelial protein lost in neoplasm beta 0.4337 7.51209e−
226425_at RSNL2 restin-like 2 0.4337 7.51209e−
203358_s_at EZH2 enhancer of zeste homolog 2 (Drosophila) −0.4337 7.51974e−
200787_s_at PEA15 phosphoprotein enriched in astrocytes 15 0.4334 7.57348e−
215947_s_at hypothetical protein FLJ14668 −0.4332 7.62202e−
232524_x_at ANAPC4 anaphase promoting complex subunit 4 −0.4330 7.67422e−
39729_at PRDX2 peroxiredoxin 2 −0.4328 7.71328e−
201849_at BNIP3 BCL2/adenovirus E1B 19 kDa interacting protein 3 0.4327 7.75252e−
241418_at Hypothetical LOC344887 0.4326 7.78405e−
200625_s_at CAP1 CAP, adenylate cyclase–associated protein 1 (yeast) 0.4324 7.81569e−
203729_at EMP3 epithelial membrane protein 3 0.4323 7.85540e−
227846_at GPR putative G protein–coupled receptor 0.4322 7.87134e−
222872_x_at FLJ22833 hypothetical protein FLJ22833 0.4321 7.89357e−
201430_s_at DPYSL3 dihydropyrimidinase-like 3 0.4318 7.97564e−
205780_at BIK BCL2-interacting killer (apoptosis-inducing) −0.4316 8.01609e−
231271_x_at HSCARG HSCARG protein −0.4315 8.04276e−
226405_s_at ARRDC1 arrestin domain containing 1 −0.4315 8.04858e−
201560_at CLIC4 chloride intracellular channel 4 0.4313 8.09753e−
223154_at MRPL1 mitochondrial ribosomal protein L1 −0.4313 8.10572e−
211506_s_at IL8 interleukin 8 0.4311 8.14676e−
221081_s_at DENND2D DENN/MADD domain containing 2D −0.4310 8.16323e−
226281_at DNER delta-notch–like EGF repeat-containing transmembrane 0.4310 8.16323e−
211376_s_at NSMCE4A chromosome 10 open reading frame 86 −0.4308 8.21282e−
221191_at DKFZp434A0131 protein −0.4308 8.21282e−
205308_at C8orf70 chromosome 8 open reading frame 70 0.4306 8.26267e−
206237_s_at NRG1 neuregulin 1 0.4306 8.27101e−
200606_at DSP desmoplakin −0.4305 8.30443e−
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242673_at −0.4303 8.35479e−
201865_x_at NR3C1 nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) 0.4301 8.41389e−
226760_at LOC203411 hypothetical protein LOC203411 0.4300 8.43933e−
212056_at KIAA0182 KIAA0182 protein −0.4296 8.54180e−
217788_s_at GALNT2 UDP–N -acetyl-α-D-galactosamine: polypeptide N -acetylgalactosaminyltransferase 2 (GalNAc-T2) 0.4295 8.56575e−
214744_s_at RPL23 ribosomal protein L23 −0.4294 8.58483e−
214446_at ELL2 elongation factor, RNA polymerase II, 2 0.4291 8.67147e−
212267_at WAPAL KIAA0261 −0.4290 8.68017e−
228009_x_at ZNRD1 zinc ribbon domain containing, 1 −0.4290 8.68889e−
211057_at ROR1 receptor tyrosine kinase–like orphan receptor 1 0.4290 8.69574e−
214927_at ITGBL1 integrin, beta-like 1 (with EGF-like repeat domains) 0.4290 8.69761e−
233167_at SELO selenoprotein O −0.4288 8.75889e−
210757_x_at DAB2 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 0.4287 8.78528e−
210095_s_at IGFBP3 insulin-like growth factor binding protein 3 0.4286 8.79409e−
204160_s_at ENPP4 ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative function) −0.4285 8.82056e−
234074_at CDNA FLJ10946 fis, clone PLACE1000005 0.4284 8.84711e−
202013_s_at EXT2 exostoses (multiple) 2 0.4281 8.92975e−
224886_at LOC339123 hypothetical LOC339123 −0.4279 8.98993e−
202828_s_at MMP14 matrix metallopeptidase 14 (membrane-inserted) 0.4279 8.98993e−
224942_at PAPPA pregnancy-associated plasma protein A, pappalysin 1 0.4279 8.99893e−
210212_x_at MTCP1 mature T-cell proliferation 1 0.4278 9.03499e−
204115_at GNG11 guanine nucleotide binding protein (G protein), gamma 11 0.4277 9.04402e−
202532_s_at DHFR dihydrofolate reductase −0.4276 9.08024e−
202326_at EHMT2 euchromatic histone-lysine N -methyltransferase 2 −0.4275 9.09646e−
202998_s_at LOXL2 lysyl oxidase–like 2 0.4274 9.12571e−
202822_at LPP LIM domain containing preferred translocation partner in lipoma 0.4274 9.13744e−
217762_s_at RAB31 RAB31, member RAS oncogene family 0.4273 9.15308e−
203441_s_at CDH2 cadherin 2, type 1, N-cadherin (neuronal) 0.4273 9.16222e−
204853_at ORC2L origin recognition complex, subunit 2–like (yeast) −0.4273 9.16222e−
227561_at DDR2 Discoidin domain receptor family, member 2 0.4271 9.22645e−
212077_at CALD1 caldesmon 1 0.4268 9.30961e−
218170_at ISOC1 isochorismatase domain containing 1 −0.4266 9.36543e−
241353_s_at LOC202775; LOC402617 hypothetical LOC202775; hypothetical LOC402617 0.4265 9.40281e−
232254_at FBXO25 F-box protein 25 0.4260 9.54419e−
218688_at DAK dihydroxyacetone kinase 2 homolog (yeast) −0.4259 9.57411e−
218028_at ELOVL1 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)–like 1 0.4258 9.59174e−
212723_at JMJD6 phosphatidylserine receptor 0.4257 9.62037e−
209127_s_at SART3 squamous cell carcinoma antigen recognized by T cells 3 −0.4257 9.62037e−
202162_s_at CNOT8 CCR4-NOT transcription complex, subunit 8 −0.4256 9.63950e−
201069_at MMP2 matrix metallopeptidase 2 (gelatinase A, 72-kDa gelatinase, 72-kDa type IV collagenase) 0.4256 9.65866e−
241763_s_at 0.4255 9.66826e−
227129_x_at LOC284701 hypothetical protein LOC284701 −0.4253 9.73566e−
209143_s_at CLNS1A; CLDND1 chloride channel, nucleotide-sensitive, 1A; chromosome 3 open reading frame 4 −0.4253 9.74533e−
212097_at CAV1 caveolin 1, caveolae protein, 22 kDa 0.4251 9.79378e−
214075_at NENF neuron-derived neurotrophic factor 0.4249 9.85220e−
204341_at TRIM16 tripartite motif-containing 16; similar to tripartite motif-containing 16; estrogen-responsive
B box protein
0.4249 9.87175e−
215489_x_at HOMER3 homer homolog 3 (Drosophila) 0.4248 9.88153e−
222900_at NRIP3 nuclear receptor interacting protein 3 0.4248 9.89905e−
213793_s_at HOMER1 homer homolog 1 (Drosophila) −0.4246 9.94043e−
228297_at CNN3 calponin 3, acidic 0.4245 9.97987e−
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Figure W1. Hierarchical clustering of NCI-60 cell lines using Euclidean distance and average linkage (according to the expression of
11,848 genes).
Figure W2. HOPACH clustering of NCI-60 cell lines according to expression of 2349 genes selected unspecifically. Red color indicates
small distance; white, large distance. Cell lines are ordered according to the final level of the cluster tree. The proportion of the esti-
mated membership within a cluster is plotted on the right part of figure. Each cluster is represented by a different color. Dotted lines
indicate the cluster boundaries at the tree level with minimum median split silhouette.
Figure W3. HOPACH clustering of NCI-60 cell lines according to genes differentially expressed between cell lines derived from different
tissues. Red color indicates small distance; white, large distance. Cell lines are ordered according to the final level of the cluster tree.
The proportion of the estimated membership within a cluster is plotted on the right part of figure. Each cluster is represented by a
different color. Dotted lines indicate the cluster boundaries at the tree level with minimum median split silhouette.
Figure W4. HOPACH clustering of NCI-60 cell lines according to genes whose expression correlated with numerical heterogeneity in-
dex. Red color indicates small distance; white, large distance. Cell lines are ordered according to the final level of the cluster tree. The
proportion of the estimated membership within a cluster is plotted on the right part of figure. Each cluster is represented by a different
color. Dotted lines indicate the cluster boundaries at the tree level with minimum median split silhouette.
Table W3. List of 213 Array Features and Names of Corresponding Genes with Expression Profiles Correlated with NH (P < .001) Across the NCI-60 Panel of Cancer Cell Lines, After Exclusion of
Array Elements Showing Differential Expression Based on Their Tissue of Origin.
Affy ID Gene Symbol Description ρ P
226148_at BTBD15 BTB (POZ) domain containing 15 −0.6236 2.2e−07
218088_s_at RRAGC Ras-related GTP binding C 0.5750 2.89e−06
200069_at SART3 squamous cell carcinoma antigen recognized by T cells 3 −0.5686 3.94e−06
226482_s_at F11R F11 receptor −0.5620 5.38e−06
220092_s_at ANTXR1 anthrax toxin receptor 1 0.5425 1.3e−05
202859_x_at IL8 interleukin 8 0.5349 1.82e−05
201172_x_at ATP6V0E1 ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit e 0.5341 1.88e−05
218491_s_at THYN1 thymocyte protein Thy28 −0.5300 2.24e−05
227560_at SFXN2 sideroflexin 2 −0.5288 2.35e−05
212978_at LRRC8B leucine-rich repeat containing 8 family, member B −0.5218 3.15e−05
212446_s_at LASS6 LAG1 longevity assurance homolog 6 (S.cerevisiae) −0.5215 3.18e−05
213149_at DLAT dihydrolipoamide S -acetyltransferase (E2 component of pyruvate dehydrogenase complex) −0.5189 3.55e−05
204767_s_at FEN1 flap structure–specific endonuclease 1 −0.5170 3.83e−05
208901_s_at TOP1 topoisomerase (DNA) I −0.5163 3.94e−05
219378_at NARG1L NMDA receptor regulated 1–like −0.5155 4.07e−05
225179_at HIP2 Huntingtin interacting protein 2 −0.5151 4.13e−05
225845_at BTBD15 BTB (POZ) domain containing 15 −0.5116 4.75e−05
211612_s_at IL13RA1 interleukin 13 receptor, alpha 1 0.5114 4.8e−05
213251_at Hypothetical LOC 441046 −0.5101 5.04e−05
223268_at PTD012 PTD012 protein −0.5091 5.26e−05
202778_s_at ZMYM2 zinc finger protein 198 −0.5058 5.99e−05
212943_at KIAA0528 KIAA0528 gene product −0.5048 6.21e−05
201887_at IL13RA1 interleukin 13 receptor, alpha 1 0.5048 6.23e−05
209225_x_at TNPO1 transportin 1 0.5047 6.23e−05
212658_at LHFPL2 lipoma HMGIC fusion partner–like 2 0.5044 6.31e−05
213696_s_at MED8 mediator of RNA polymerase II transcription, subunit 8 homolog (yeast) 0.5043 6.33e−05
209013_x_at TRIO triple functional domain (PTPRF interacting) 0.5034 6.56e−05
224944_at TMPO Thymopoietin −0.4982 8.01e−05
209019_s_at PINK1 PTEN-induced putative kinase 1 0.4974 8.28e−05
213626_at CBR4 carbonic reductase 4 −0.4966 8.54e−05
212470_at SPAG9 sperm-associated antigen 9 0.4948 9.12e−05
204359_at FLRT2 fibronectin leucine-rich transmembrane protein 2 0.4945 9.25e−05
203773_x_at BLVRA biliverdin reductase A 0.4921 .000101
202163_s_at CNOT8 CCR4-NOT transcription complex, subunit 8 −0.4906 .000107
218458_at GMCL1 germ cell–less homolog 1 (Drosophila) −0.4900 .000109
221737_at GNA12 guanine nucleotide binding protein (G protein) alpha12 0.4896 .000111
221753_at SSH1 slingshot homolog 1 (Drosophila) 0.4895 .000111
212430_at RBM38 RNA-binding region (RNP1, RRM) containing 1 −0.4884 .000116
200943_at HMGN1 high-mobility group nucleosome binding domain 1 −0.4884 .000116
222514_at RRAGC Ras-related GTP binding C 0.4881 .000117
200990_at TRIM28 tripartite motif-containing 28 −0.4871 .000122
209832_s_at CDT1 DNA replication factor −0.4865 .000125
224504_s_at MGC13125 hypothetical protein MGC13125 −0.4862 .000126
217785_s_at YKT6 SNARE protein Ykt6 0.4861 .000126
210053_at TAF5 TAF5 RNA polymerase II, TATA box binding protein (TBP)–associated factor, 100 kDa −0.4853 .00013
226651_at HOMER1 homer homolog 1 (Drosophila) −0.4844 .000135
201885_s_at CYB5R3 cytochrome b5 reductase 3 0.4843 .000135
208549_x_at PTMA prothymosin, alpha (gene sequence 28); similar toprothymosin alpha; hypothetical gene supported
by BC013859; hypothetical gene supported by BC013859; BC070480
−0.4839 .000137
205083_at AOX1 aldehyde oxidase 1 0.4832 .000141
208838_at CAND1 cullin-associated and neddylation-dissociated 1 −0.4822 .000146
224677_x_at C11orf31 chromosome 11 open reading frame 31 −0.4820 .000147
206157_at PTX3 pentraxin-related gene, rapidly induced by IL-1 beta 0.4807 .000154
209420_s_at SMPD1 sphingomyelin phosphodiesterase 1, acid lysosomal (acid sphingomyelinase) 0.4806 .000155
224610_at full-length cDNA clone CL0BB014ZH04 of neuroblastoma of Homo sapiens (human) −0.4772 .000175
201930_at MCM6 MCM6 minichromosome maintenance deficient 6 (MIS5 homolog, S. pombe) (S. cerevisiae) −0.4768 .000177
226099_at ELL2 elongation factor, RNA polymerase II, 2 0.4749 .00019
201051_at ANP32A acidic (leucine-rich) nuclear phosphoprotein 32 family, member A −0.4744 .000193
201185_at HTRA1 HtrA serine peptidase 1 0.4742 .000194
217843_s_at MED4 mediator of RNA polymerase II transcription, subunit 4 homolog (yeast) −0.4724 .000207
222036_s_at MCM4 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae) −0.4720 .00021
200668_s_at UBE2D3 ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) −0.4718 .000211
205207_at IL6 interleukin 6 (interferon, beta 2) 0.4717 .000212
218420_s_at C13orf23 chromosome 13 open reading frame 23 −0.4697 .000228
226574_at PSPC1; LOC374491 paraspeckle component 1; TPTE and PTEN homologous inositol lipid phosphatase pseudogene −0.4697 .000228
202830_s_at SLC37A4 solute carrier family 37 (glycerol-6-phosphatetransporter), member 4 −0.4681 .000241
205129_at NPM3 nucleophosmin/nucleoplasmin, 3 −0.4678 .000244
209897_s_at SLIT2 slit homolog 2 (Drosophila) 0.4658 .000261
217872_at PIH1D1 hypothetical protein FLJ20643 −0.4656 .000263
225398_at RPUSD4 RNA pseudouridylate synthase domain containing 4 −0.4653 .000265
235706_at CPM carboxypeptidase M 0.4650 .000268
220750_s_at LEPRE1 leucine proline–enriched proteoglycan (leprecan) 1 0.4648 .00027
Affy ID Gene Symbol Description ρ P
200099_s_at RPS3A ribosomal protein S3A −0.4636 .000282
204948_s_at FST follistatin 0.4635 .000283
204658_at transformer-2 alpha −0.4627 .00029
235138_at PUM2 Pumilio homolog 2 (Drosophila) −0.4624 .000294
221096_s_at TMCO6 hypothetical protein PRO1580 −0.4619 .000298
222222_s_at HOMER3 homer homolog 3 (Drosophila) 0.4615 .000302
231045_x_at C11orf31 chromosome 11 open reading frame 31 −0.4614 .000303
214212_x_at PLEKHC1 pleckstrin homology domain containing, family C (with FERM domain) member 1 0.4613 .000304
217882_at TMEM111 30-kDa protein 0.4613 .000304
216232_s_at GCN1L1 GCN1 general control of amino acid synthesis 1–like 1 (yeast) −0.4612 .000305
226982_at ELL2 elongation factor, RNA polymerase II, 2 0.4611 .000306
210416_s_at CHEK2 CHK2 checkpoint homolog (S. pombe) −0.4605 .000313
229663_at LONPL peroxisomal LON protease like 0.4600 .000318
213052_at PRKAR2A protein kinase, cAMP-dependent, regulatory, type II, alpha 0.4587 .000333
208973_at PRNPIP prion protein interacting protein 0.4585 .000335
204009_s_at KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog −0.4582 .000339
223206_s_at HSCARG HSCARG protein −0.4581 .00034
218848_at THOC6 WD repeat domain 58 −0.4580 .000341
218448_at C20orf11 chromosome 20 open reading frame 11 −0.4573 .000348
211729_x_at BLVRA biliverdin reductase A 0.4569 .000354
232816_s_at DDX11 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like helicase homolog, S. cerevisiae) −0.4554 .000372
214150_x_at ATP6V0E1 ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit e 0.4553 .000373
218407_x_at NENF neuron-derived neurotrophic factor 0.4545 .000383
221641_s_at ACOT9 acyl-CoA thioesterase 9 0.4539 .000391
208804_s_at SFRS6 splicing factor, arginine/serine–rich 6 −0.4530 .000402
200753_x_at SFRS2 splicing factor, arginine/serine–rich 2 −0.4530 .000403
202330_s_at UNG uracil-DNA glycosylase −0.4529 .000404
202164_s_at CNOT8 CCR4-NOT transcription complex, subunit 8 −0.4527 .000407
224840_at FKBP5 FK506 binding protein 5 −0.4525 .00041
208896_at DDX18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 −0.4523 .000412
204768_s_at FEN1 flap structure–specific endonuclease 1 −0.4521 .000415
212593_s_at PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) −0.4515 .000423
218069_at XTP3-transactivated protein A −0.4504 .000439
221881_s_at CLIC4 chloride intracellular channel 4 0.4499 .000446
202303_x_at SMARCA5 SWI/SNF–related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 5 −0.4496 .000451
201493_s_at PUM2 pumilio homolog 2 (Drosophila) −0.4495 .000452
213610_s_at KLHL23 kelch-like 23 (Drosophila) −0.4494 .000454
227740_at UHMK1 U2AF homology motif (UHM) kinase 1 0.4489 .000461
201376_s_at HNRPF heterogeneous nuclear ribonucleoprotein F −0.4488 .000463
201559_s_at CLIC4 chloride intracellular channel 4 0.4486 .000465
57163_at ELOVL1 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)–like 1 0.4483 .00047
225563_at PAN3 PABP1-dependent poly A–specific ribonuclease subunit PAN3 −0.4483 .00047
200956_s_at SSRP1 structure-specific recognition protein 1 −0.4479 .000476
213329_at SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 0.4476 .00048
225391_at LOC93622 hypothetical protein BC006130 −0.4474 .000485
217784_at YKT6 SNARE protein Ykt6 0.4471 .00049
216262_s_at TGIF2 TGFB-induced factor 2 (TALE family homeobox) −0.4466 .000497
202259_s_at phosphonoformate immuno-associated protein 5 −0.4465 .000498
205909_at POLE2 polymerase (DNA-directed), epsilon 2 (p59 subunit) −0.4465 .000499
204819_at FGD1 FYVE, RhoGEF and PH domain containing 1 (faciogenital dysplasia) 0.4464 .0005
218298_s_at C14orf159 chromosome 14 open reading frame 159 −0.4462 .000504
209750_at NR1D2 nuclear receptor subfamily 1, group D, member 2 0.4459 .000508
201035_s_at HADH L-3-hydroxyacyl–Coenzyme A dehydrogenase, short chain −0.4458 .000511
210904_s_at IL13RA1 interleukin 13 receptor, alpha 1 0.4442 .000537
202258_s_at phosphonoformate immuno-associated protein 5 −0.4441 .000539
226912_at ZDHHC23 zinc finger, DHHC-type containing 23 −0.4438 .000544
218168_s_at CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) −0.4436 .000548
228174_at GOLGA1 Golgi autoantigen, golgin subfamily a, 1 −0.4428 .000562
200957_s_at SSRP1 structure-specific recognition protein 1 −0.4422 .000573
232113_at Hypothetical gene supported by BX647608 0.4421 .000576
219557_s_at NRIP3 nuclear receptor interacting protein 3 0.4418 .00058
223711_s_at THY28 thymocyte protein Thy28 −0.4415 .000586
212709_at NUP160 nucleoporin 160 kDa −0.4411 .000594
200679_x_at HMGB1 high-mobility group box 1 −0.4409 .000598
222204_s_at RRN3 RRN3 RNA polymerase I transcription factor homolog (yeast) −0.4403 .000608
214882_s_at SFRS2 splicing factor, arginine/serine–rich 2 −0.4403 .000608
208178_x_at TRIO triple functional domain (PTPRF interacting) 0.4401 .000614
213238_at ATP10D ATPase, class V, type 10D 0.4399 .000618
201450_s_at TIA1 TIA1 cytotoxic granule-associated RNA binding protein −0.4398 .000619
201712_s_at RANBP2 RAN binding protein 2 −0.4395 .000624
200977_s_at TAX1BP1 Tax1 (human T-cell leukemia virus type I) binding protein 1 0.4393 .000628
202948_at IL1R1 interleukin 1 receptor, type I 0.4390 .000635
203317_at PSD4 pleckstrin and Sec7 domain containing 4 −0.4387 .000641
Table W3. (continued )
Affy ID Gene Symbol Description ρ P
233364_s_at Hypothetical gene supported by BX647608 0.4386 .000643
208795_s_at MCM7 MCM7 minichromosome maintenance deficient 7 (S. cerevisiae) −0.4386 .000643
203231_s_at ATXN1 ataxin 1 0.4382 .000651
208747_s_at C1S complement component 1, s subcomponent 0.4380 .000656
214109_at LRBA LPS-responsive vesicle trafficking, beach and anchor containing −0.4377 .000662
213338_at TMEM158 Ras-induced senescence 1 0.4374 .000668
224940_s_at PAPPA pregnancy-associated plasma protein A, pappalysin 1 0.4374 .000669
207749_s_at PPP2R3A protein phosphatase 2 (formerly 2A), regulatory subunit B″, alpha 0.4372 .000673
203856_at VRK1 vaccinia-related kinase 1 −0.4371 .000675
212603_at MRPS31 mitochondrial ribosomal protein S31 −0.4368 .00068
212789_at NCAPD3 KIAA0056 protein −0.4366 .000685
201170_s_at BHLHB2 basic helix-loop-helix domain containing, class B, 2 0.4364 .00069
202302_s_at RSRC2 similar to splicing factor, arginine/serine–rich 4 −0.4363 .000692
212443_at NBEAL2 neurobeachin-like 2 −0.4362 .000694
207949_s_at ICA1 islet cell autoantigen 1, 69 kDa −0.4360 .000699
209421_at MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) −0.4359 .0007
218443_s_at DAZAP1 DAZ-associated protein 1 −0.4359 .000701
203229_s_at CLK2 CDC-like kinase 2 −0.4356 .000707
213798_s_at CAP1 CAP, adenylate cyclase–associated protein 1 (yeast) 0.4356 .000708
216969_s_at KIF22 kinesin family member 22 −0.4355 .00071
208908_s_at CAST calpastatin 0.4353 .000714
203388_at ARRB2 arrestin, beta 2 −0.4351 .00072
218714_at PRR14 hypothetical protein MGC3121 −0.4342 .00074
212920_at −0.4338 .00075
217892_s_at LIMA1 epithelial protein lost in neoplasm beta 0.4337 .000751
215947_s_at hypothetical protein FLJ14668 −0.4332 .000762
232524_x_at ANAPC4 anaphase promoting complex subunit 4 −0.4330 .000767
39729_at PRDX2 peroxiredoxin 2 −0.4328 .000771
241418_at Hypothetical LOC344887 0.4326 .000778
200625_s_at CAP1 CAP, adenylate cyclase–associated protein 1 (yeast) 0.4324 .000782
203729_at EMP3 epithelial membrane protein 3 0.4323 .000786
227846_at GPR putative G protein coupled receptor 0.4322 .000787
231271_x_at HSCARG HSCARG protein −0.4315 .000804
226405_s_at ARRDC1 arrestin domain containing 1 −0.4315 .000805
223154_at MRPL1 mitochondrial ribosomal protein L1 −0.4313 .000811
211506_s_at IL8 interleukin 8 0.4311 .000815
226281_at DNER delta-notch–like EGF repeat-containing transmembrane 0.4310 .000816
221191_at DKFZp434A0131 protein −0.4308 .000821
211376_s_at NSMCE4A chromosome 10 open reading frame 86 −0.4308 .000821
205308_at C8orf70 chromosome 8 open reading frame 70 0.4306 .000826
206237_s_at NRG1 neuregulin 1 0.4306 .000827
242673_at −0.4303 .000835
212056_at KIAA0182 KIAA0182 protein −0.4296 .000854
214744_s_at RPL23 ribosomal protein L23 −0.4294 .000858
214446_at ELL2 elongation factor, RNA polymerase II, 2 0.4291 .000867
212267_at WAPAL KIAA0261 −0.4290 .000868
211057_at ROR1 receptor tyrosine kinase–like orphan receptor 1 0.4290 .00087
214927_at ITGBL1 integrin, beta-like 1 (with EGF-like repeat domains) 0.4290 .00087
233167_at SELO selenoprotein O −0.4288 .000876
210095_s_at IGFBP3 insulin-like growth factor binding protein 3 0.4286 .000879
204160_s_at ENPP4 ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative function) −0.4285 .000882
202013_s_at EXT2 exostoses (multiple) 2 0.4281 .000893
224886_at LOC339123 hypothetical LOC339123 −0.4279 .000899
224942_at PAPPA pregnancy-associated plasma protein A, pappalysin 1 0.4279 .0009
202532_s_at DHFR dihydrofolate reductase −0.4276 .000908
202326_at EHMT2 euchromatic histone-lysine N -methyltransferase 2 −0.4275 .00091
204853_at ORC2L origin recognition complex, subunit 2–like (yeast) −0.4273 .000916
218170_at ISOC1 isochorismatase domain containing 1 −0.4266 .000937
232254_at FBXO25 F-box protein 25 0.4260 .000954
218688_at DAK dihydroxyacetone kinase 2 homolog (yeast) −0.4259 .000957
218028_at ELOVL1 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)–like 1 0.4258 .000959
212723_at JMJD6 phosphatidylserine receptor 0.4257 .000962
209127_s_at SART3 squamous cell carcinoma antigen recognized by T cells 3 −0.4257 .000962
202162_s_at CNOT8 CCR4-NOT transcription complex, subunit 8 −0.4256 .000964
227129_x_at LOC284701 hypothetical protein LOC284701 −0.4253 .000974
209143_s_at CLNS1A; CLDND1 chloride channel, nucleotide-sensitive, 1A; chromosome 3 open reading frame 4 −0.4253 .000975
214075_at NENF neuron-derived neurotrophic factor 0.4249 .000985
222900_at NRIP3 nuclear receptor interacting protein 3 0.4248 .00099
213793_s_at HOMER1 homer homolog 1 (Drosophila) −0.4246 .000994
Table W3. (continued )
Table W4. Gene Ontology Categories Associated with Genes Whose Expression Profiles Correlated with NH (P < .01) Across the NCI-60 Panel of Cancer Cell Lines.
Categories Associated with Expression of Genes Negatively Correlated with NH (P < .01)
Category GO Term Count % P
GOTERM_BP_ALL cellular metabolism 275 49.73 4.80e−08
GOTERM_BP_ALL macromolecule metabolism 197 35.62 8.32e−08
GOTERM_BP_ALL nucleobase, nucleoside, nucleotide and nucleic acid metabolism 185 33.45 2.96e−19
GOTERM_BP_ALL biopolymier metabolism 149 26.94 4.01e−09
GOTERM_BP_ALL regulation of biological process 131 23.69 .0104873
GOTERM_BP_ALL regulation of cellular process 128 23.15 .0027890
GOTERM_BP_ALL regulation of physiological process 128 23.15 5.97e−04
GOTERM_BP_ALL regulation of cellular physiological process 126 22.78 5.81e−04
GOTERM_BP_ALL regulation of metabolism 96 17.36 1.95e−04
GOTERM_BP_ALL regulation of cellular metabolism 95 17.18 6.59e−05
GOTERM_BP_ALL transcription 92 16.64 5.53e−05
GOTERM_BP_ALL regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism 90 16.27 5.56e−05
GOTERM_BP_ALL transcription, DNA-dependent 87 15.73 3.80e−05
GOTERM_BP_ALL regulation of transcription 86 15.55 1.68e−04
GOTERM_BP_ALL regulation of transcription, DNA-dependent 83 15.01 7.26e−05
GOTERM_BP_ALL DNA metabolism 58 10.49 1.87e−10
GOTERM_BP_ALL RNA metabolism 50 9.04 1.14e−08
GOTERM_BP_ALL cell cycle 48 8.68 6.20e−04
GOTERM_BP_ALL RNA processing 47 8.50 2.27e−10
GOTERM_BP_ALL mRNA metabolism 36 6.51 4.95e−10
GOTERM_BP_ALL mRNA processing 31 5.61 1.13e−08
GOTERM_BP_ALL DNA replication 26 4.70 1.46e−07
GOTERM_BP_ALL RNA splicing 25 4.52 4.15e−07
GOTERM_BP_ALL response to endogenous stimulus 24 4.34 6.50e−04
GOTERM_BP_ALL response to DNA damage stimulus 24 4.34 4.14e−04
GOTERM_BP_ALL DNA repair 23 4.16 1.82e−04
GOTERM_BP_ALL chromosome organization and biogenesis 22 3.98 .0013376
GOTERM_BP_ALL chromosome organization and biogenesis (sensu Eukaryota) 20 3.62 .0023155
GOTERM_BP_ALL nuclear mRNA splicing, through spliceosome 20 3.62 1.71e−05
GOTERM_BP_ALL RNA splicing, through transesterification reactions with bulged adenosine as nucleophile 20 3.62 1.71e−05
GOTERM_BP_ALL RNA splicing, through transesterification reactions 20 3.62 1.71e−05
GOTERM_BP_ALL DNA packaging 18 3.25 .0017667
GOTERM_BP_ALL protein complex assembly 16 2.89 .0468127
GOTERM_BP_ALL M phase 16 2.89 .0229671
GOTERM_BP_ALL establishment and/or maintenance of chromatin architecture 16 2.89 .0075817
GOTERM_BP_ALL DNA-dependent DNA replication 15 2.71 3.74e−05
GOTERM_BP_ALL chromatin assembly or disassembly 9 1.63 .0425323
GOTERM_BP_ALL ribosome biogenesis and assembly 9 1.63 .0425323
GOTERM_BP_ALL DNA recombination 8 1.45 .0060408
GOTERM_BP_ALL transcription initiation 7 1.27 .0226955
GOTERM_BP_ALL DNA replication initiation 7 1.27 9.09e−04
GOTERM_BP_ALL M phase of meiotic cell cycle 5 0.90 .0438018
GOTERM_BP_ALL mRNA catabolism 5 0.90 .0308043
GOTERM_BP_ALL DNA unwinding during replication 4 0.72 .0090748
GOTERM_CC_ALL intracellular 304 54.97 2.02e−12
GOTERM_CC_ALL organelle 282 50.99 2.02e−17
GOTERM_CC_ALL intracellular organelle 282 50.99 1.90e−17
GOTERM_CC_ALL membrane-bound organelle 259 46.84 2.70e−16
GOTERM_CC_ALL intracellular membrane–bound organelle 259 46.84 2.61e−16
GOTERM_CC_ALL nucleus 202 36.53 2.54e−19
GOTERM_CC_ALL protein complex 93 16.82 9.34e−05
GOTERM_CC_ALL intracellular non–membrane-bound organelle 68 12.30 .0014360
GOTERM_CC_ALL non–membrane-bound organelle 68 12.30 .0014360
GOTERM_CC_ALL mitochondrion 39 7.05 .0217935
GOTERM_CC_ALL ribonucleoprotein complex 35 6.33 1.77e−05
GOTERM_CC_ALL membrane-enclosed lumen 31 5.61 .0266555
GOTERM_CC_ALL organelle lumen 31 5.61 .0266555
GOTERM_CC_ALL chromosome 31 5.61 3.74e−08
GOTERM_CC_ALL nuclear lumen 27 4.88 .005185
GOTERM_CC_ALL nucleoplasm 18 3.25 .0267792
GOTERM_CC_ALL ribosome 14 2.53 .0304751
GOTERM_CC_ALL chromatin 14 2.53 3.90e−04
GOTERM_CC_ALL nuclear chromosome 7 1.27 .0300376
GOTERM_CC_ALL condensed chromosome 5 0.90 .0186952
GOTERM_CC_ALL synaptic vesicle 4 0.72 .0413124
GOTERM_CC_ALL obsolete cellular component 4 0.72 .0413124
GOTERM_CC_ALL delta-DNA polymerase cofactor complex 3 0.54 .0243645
GOTERM_MF_ALL nucleic acid binding 153 27.67 8.89e−11
GOTERM_MF_ALL nucleotide binding 92 16.64 .0023895
GOTERM_MF_ALL DNA binding 92 16.64 7.93e−06
GOTERM_MF_ALL transcription regulator activity 55 9.95 .0049911
GOTERM_MF_ALL RNA binding 55 9.95 6.23e−09
Table W4. (continued )
Categories Associated with Expression of Genes Negatively Correlated with NH (P < .01)
Category GO Term Count % P
GOTERM_MF_ALL ATPase activity 20 3.62 .0098998
GOTERM_MF_ALL transcriptional activator activity 17 3.07 .0134395
GOTERM_MF_ALL ATPase activity, coupled 16 2.89 .0496740
GOTERM_MF_ALL structural constituent of ribosome 15 2.71 .0339051
GOTERM_MF_ALL mRNA binding 8 1.45 1.73e−04
GOTERM_MF_ALL acetyltransferase activity 7 1.27 .0203796
GOTERM_MF_ALL chromatin binding 7 1.27 .0149992
GOTERM_MF_ALL DNA-dependent ATPase activity 7 1.27 .0030113
GOTERM_MF_ALL double-stranded DNA binding 5 0.90 .0259470
BIOCARTA h_prc2Pathway: The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails 4 0.72 .0301009
Categories Associated with Expression of Genes Positively Correlated with NH (P < .01)
Category Term Count % P
GOTERM_BP_ALL cell communication 136 23.01 3.55e−05
GOTERM_BP_ALL signal transduction 127 21.49 4.00e−05
GOTERM_BP_ALL localization 117 19.80 3.79e−04
GOTERM_BP_ALL establishment of localization 117 19.80 3.08e−04
GOTERM_BP_ALL development 97 16.41 1.75e−09
GOTERM_BP_ALL cell organization and biogenesis 73 12.35 1.07e−05
GOTERM_BP_ALL cell adhesion 68 11.51 1.39e−19
GOTERM_BP_ALL intracellular signaling cascade 52 8.80 5.60e−04
GOTERM_BP_ALL negative regulation of biological process 46 7.78 3.08e−06
GOTERM_BP_ALL negative regulation of cellular process 45 7.61 1.03e−06
GOTERM_BP_ALL phosphorus metabolism 42 7.11 .0049447
GOTERM_BP_ALL phosphate metabolism 42 7.11 .0049447
GOTERM_BP_ALL negative regulation of physiological process 41 6.94 6.83e−06
GOTERM_BP_ALL negative regulation of cellular physiological process 40 6.77 7.04e−06
GOTERM_BP_ALL morphogenesis 39 6.60 3.21e−06
GOTERM_BP_ALL positive regulation of biological process 35 5.92 2.68e−04
GOTERM_BP_ALL death 32 5.41 6.70e−04
GOTERM_BP_ALL organ development 32 5.41 1.34e−04
GOTERM_BP_ALL cell death 31 5.25 .0012428
GOTERM_BP_ALL positive regulation of cellular process 31 5.25 3.58e−04
GOTERM_BP_ALL cellular localization 30 5.08 .0056816
GOTERM_BP_ALL programmed cell death 30 5.08 .0014543
GOTERM_BP_ALL apoptosis 30 5.08 .0013914
GOTERM_BP_ALL establishment of cellular localization 29 4.91 .0092904
GOTERM_BP_ALL intracellular transport 29 4.91 .0078798
GOTERM_BP_ALL response to external stimulus 29 4.91 8.90e−04
GOTERM_BP_ALL cell proliferation 28 4.74 .0032481
GOTERM_BP_ALL locomotion 28 4.74 8.90e−10
GOTERM_BP_ALL localization of cell 28 4.74 8.90e−10
GOTERM_BP_ALL cell motility 28 4.74 8.90e−10
GOTERM_BP_ALL cell-cell adhesion 28 4.74 2.52e−10
GOTERM_BP_ALL cell differentiation 26 4.40 .0054730
GOTERM_BP_ALL cellular morphogenesis 25 4.23 1.16e−06
GOTERM_BP_ALL homophilic cell adhesion 25 4.23 7.28e−13
GOTERM_BP_ALL system development 22 3.72 .0328183
GOTERM_BP_ALL nervous system development 22 3.72 .0306327
GOTERM_BP_ALL regulation of cell cycle 21 3.55 .0464284
GOTERM_BP_ALL regulation of progression through cell cycle 21 3.55 .0456837
GOTERM_BP_ALL response to abiotic stimulus 21 3.55 .0336106
GOTERM_BP_ALL vesicle-mediated transport 21 3.55 .0040294
GOTERM_BP_ALL protein kinase cascade 21 3.55 1.70e−04
GOTERM_BP_ALL cytoskeleton organization and biogenesis 20 3.38 .0207670
GOTERM_BP_ALL response to wounding 20 3.38 .0189762
GOTERM_BP_ALL regulation of programmed cell death 20 3.38 .0066011
GOTERM_BP_ALL regulation of apoptosis 20 3.38 .0062443
GOTERM_BP_ALL regulation of cell proliferation 20 3.38 9.79e−04
GOTERM_BP_ALL regulation of signal transduction 20 3.38 2.33e−05
GOTERM_BP_ALL response to chemical stimulus 19 3.21 .0315919
GOTERM_BP_ALL cell migration 16 2.71 2.07e−07
GOTERM_BP_ALL small GTPase-mediated signal transduction 15 2.54 .0288176
GOTERM_BP_ALL growth 15 2.54 .0013231
GOTERM_BP_ALL cell growth 14 2.37 5.31e−04
GOTERM_BP_ALL regulation of cell size 14 2.37 5.31e−04
GOTERM_BP_ALL organ morphogenesis 13 2.20 .0215043
GOTERM_BP_ALL enzyme-linked receptor protein signaling pathway 13 2.20 .0070186
GOTERM_BP_ALL I-κB kinase/NF-κB cascade 13 2.20 1.12e−04
GOTERM_BP_ALL homeostasis 12 2.03 .0261415
Table W4. (continued )
Categories Associated with Expression of Genes Positively Correlated with NH (P < .01)
Category Term Count % P
GOTERM_BP_ALL regulation of I-κB kinase/NF-κB cascade 12 2.03 2.82e−05
GOTERM_BP_ALL secretory pathway 11 1.86 .0439977
GOTERM_BP_ALL actin filament–based process 11 1.86 .0229747
GOTERM_BP_ALL inorganic anion transport 11 1.86 .0206056
GOTERM_BP_ALL actin cytoskeleton organization and biogenesis 11 1.86 .0151636
GOTERM_BP_ALL negative regulation of progression through cell cycle 11 1.86 .0145675
GOTERM_BP_ALL negative regulation of cell proliferation 11 1.86 .0123569
GOTERM_BP_ALL dephosphorylation 11 1.86 .0104091
GOTERM_BP_ALL negative regulation of programmed cell death 11 1.86 .0079367
GOTERM_BP_ALL negative regulation of apoptosis 11 1.86 .0075730
GOTERM_BP_ALL protein amino acid dephosphorylation 11 1.86 .0072224
GOTERM_BP_ALL regulation of growth 11 1.86 .0041368
GOTERM_BP_ALL antiapoptosis 11 1.86 .0027945
GOTERM_BP_ALL positive regulation of signal transduction 11 1.86 4.31e−04
GOTERM_BP_ALL cell homeostasis 10 1.69 .0347712
GOTERM_BP_ALL positive regulation of cell proliferation 10 1.69 .0154140
GOTERM_BP_ALL regulation of cell growth 10 1.69 .0075542
GOTERM_BP_ALL wound healing 10 1.69 .0023127
GOTERM_BP_ALL positive regulation of I-κB kinase/NF-κB cascade 10 1.69 4.02e−04
GOTERM_BP_ALL skeletal development 9 1.52 .0398567
GOTERM_BP_ALL transmembrane receptor protein tyrosine kinase signaling pathway 9 1.52 .0370367
GOTERM_BP_ALL locomotory behavior 9 1.52 .0318068
GOTERM_BP_ALL chemotaxis 9 1.52 .0260108
GOTERM_BP_ALL taxis 9 1.52 .0260108
GOTERM_BP_ALL cell development 9 1.52 .0191954
GOTERM_BP_ALL phosphate transport 9 1.52 .0095473
GOTERM_BP_ALL neurogenesis 9 1.52 .0095473
GOTERM_BP_ALL muscle development 9 1.52 .0076198
GOTERM_BP_ALL regulation of body fluids 8 1.35 .0342186
GOTERM_BP_ALL neuron differentiation 8 1.35 .0227081
GOTERM_BP_ALL hemostasis 8 1.35 .0205718
GOTERM_BP_ALL Golgi vesicle transport 8 1.35 .0195580
GOTERM_BP_ALL coagulation 8 1.35 .0167270
GOTERM_BP_ALL blood coagulation 8 1.35 .0150089
GOTERM_BP_ALL regulation of development 8 1.35 .0082556
GOTERM_BP_ALL cell cycle arrest 8 1.35 .0029397
GOTERM_BP_ALL ER to Golgi vesicle–mediated transport 8 1.35 .0022683
GOTERM_BP_ALL neuron development 7 1.18 .0309592
GOTERM_BP_ALL integrin-mediated signaling pathway 7 1.18 .0167194
GOTERM_BP_ALL blood vessel morphogenesis 7 1.18 .0157055
GOTERM_BP_ALL blood vessel development 7 1.18 .0157055
GOTERM_BP_ALL vasculature development 7 1.18 .0157055
GOTERM_BP_ALL angiogenesis 7 1.18 .0129206
GOTERM_BP_ALL aminoglycan metabolism 5 0.85 .0275782
GOTERM_BP_ALL glycosaminoglycan metabolism 5 0.85 .0254349
GOTERM_BP_ALL regulation of locomotion 5 0.85 .0094927
GOTERM_BP_ALL regulation of cell motility 5 0.85 .0094927
GOTERM_BP_ALL regulation of cell migration 5 0.85 .0094927
GOTERM_BP_ALL positive regulation of development 5 0.85 .0064945
GOTERM_BP_ALL regulation of axonogenesis 3 0.51 .0367302
GOTERM_BP_ALL regulation of Ras protein signal transduction 3 0.51 .0367302
GOTERM_BP_ALL regulation of epithelial cell proliferation 3 0.51 .0109926
GOTERM_BP_ALL epithelial cell proliferation 3 0.51 .0109926
GOTERM_BP_ALL copper ion homeostasis 3 0.51 .0074668
GOTERM_BP_ALL positive regulation of epithelial cell proliferation 3 0.51 .0074668
GOTERM_CC_ALL cytoplasm 128 21.66 .0153518
GOTERM_CC_ALL plasma membrane 79 13.37 9.37e−05
GOTERM_CC_ALL extracellular region 70 11.84 6.77e−07
GOTERM_CC_ALL cytoskeleton 58 9.81 6.81e−08
GOTERM_CC_ALL intrinsic to plasma membrane 49 8.29 .0269904
GOTERM_CC_ALL integral to plasma membrane 49 8.29 .0246202
GOTERM_CC_ALL extracellular matrix 35 5.92 9.43e−11
GOTERM_CC_ALL extracellular matrix (sensu Metazoa) 35 5.92 5.21e−11
GOTERM_CC_ALL endoplasmic reticulum 33 5.58 1.66e−04
GOTERM_CC_ALL Golgi apparatus 24 4.06 .0121383
GOTERM_CC_ALL extracellular space 24 4.06 .0076828
GOTERM_CC_ALL actin cytoskeleton 18 3.05 3.01e−04
GOTERM_CC_ALL microtubule cytoskeleton 17 2.88 .0054881
GOTERM_CC_ALL microtubule 13 2.20 .0076041
GOTERM_CC_ALL vacuole 10 1.69 .0220081
GOTERM_CC_ALL basement membrane 10 1.69 4.10e−05
GOTERM_CC_ALL collagen 8 1.35 1.15e−04
Table W4. (continued )
Categories Associated with Expression of Genes Positively Correlated with NH (P < .01)
Category Term Count % P
GOTERM_CC_ALL extrinsic to membrane 6 1.02 .0104410
GOTERM_CC_ALL basal lamina 5 0.85 .0106105
GOTERM_CC_ALL heterotrimeric G-protein complex 4 0.68 .0425953
GOTERM_CC_ALL laminin complex 3 0.51 .0265177
GOTERM_CC_ALL anchoring collagen 3 0.51 .0265177
GOTERM_CC_ALL sheet-forming collagen 3 0.51 .0160747
GOTERM_CC_ALL laminin-1 3 0.51 .0160747
GOTERM_MF_ALL cation binding 121 20.47 1.18e−04
GOTERM_MF_ALL hydrolase activity 73 12.35 .0283996
GOTERM_MF_ALL nucleotide binding 72 12.18 .0088437
GOTERM_MF_ALL calcium ion binding 68 11.51 1.91e−15
GOTERM_MF_ALL purine nucleotide binding 67 11.34 .0019492
GOTERM_MF_ALL adenyl nucleotide binding 50 8.46 .0218535
GOTERM_MF_ALL ATP binding 47 7.95 .0382664
GOTERM_MF_ALL structural molecule activity 43 7.28 7.94e−04
GOTERM_MF_ALL enzyme regulator activity 40 6.77 1.49e−06
GOTERM_MF_ALL kinase activity 38 6.43 .0151332
GOTERM_MF_ALL phosphotransferase activity, alcohol group as acceptor 31 5.25 .0185969
GOTERM_MF_ALL cytoskeletal protein binding 29 4.91 1.21e−07
GOTERM_MF_ALL protein kinase activity 28 4.74 .0117125
GOTERM_MF_ALL hydrolase activity, acting on acid anhydrides 26 4.40 .0143863
GOTERM_MF_ALL hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides 26 4.40 .0119770
GOTERM_MF_ALL pyrophosphatase activity 26 4.40 .0112973
GOTERM_MF_ALL nucleoside-triphosphatase activity 25 4.23 .0120011
GOTERM_MF_ALL actin binding 22 3.72 1.61e−06
GOTERM_MF_ALL protein serine/threonine kinase activity 21 3.55 .0095445
GOTERM_MF_ALL phosphoric ester hydrolase activity 19 3.21 .0024685
GOTERM_MF_ALL guanyl nucleotide binding 18 3.05 .0328025
GOTERM_MF_ALL phosphoric monoester hydrolase activity 17 2.88 6.99e−04
GOTERM_MF_ALL GTPase regulator activity 16 2.71 .0068181
GOTERM_MF_ALL carbohydrate binding 16 2.71 .0035107
GOTERM_MF_ALL obsolete molecular function 15 2.54 .0188299
GOTERM_MF_ALL magnesium ion binding 15 2.54 .0145196
GOTERM_MF_ALL enzyme inhibitor activity 15 2.54 .0075281
GOTERM_MF_ALL phosphoprotein phosphatase activity 14 2.37 6.78e−04
GOTERM_MF_ALL GTPase activity 13 2.20 .0014018
GOTERM_MF_ALL extracellular matrix structural constituent 13 2.20 1.44e−05
GOTERM_MF_ALL small GTPase regulator activity 12 2.03 .0093352
GOTERM_MF_ALL pattern binding 12 2.03 1.62e−04
GOTERM_MF_ALL polysaccharide binding 12 2.03 6.74e−05
GOTERM_MF_ALL glycosaminoglycan binding 12 2.03 4.76e−05
GOTERM_MF_ALL cAMP-dependent protein kinase activity 11 1.86 .0325455
GOTERM_MF_ALL cyclic nucleotide–dependent protein kinase activity 11 1.86 .0325455
GOTERM_MF_ALL protein kinase CK2 activity 11 1.86 .0288109
GOTERM_MF_ALL protease inhibitor activity 10 1.69 .0189656
GOTERM_MF_ALL endopeptidase inhibitor activity 10 1.69 .0182981
GOTERM_MF_ALL calmodulin binding 10 1.69 .0046835
GOTERM_MF_ALL protein tyrosine phosphatase activity 10 1.69 .0010162
GOTERM_MF_ALL heparin binding 10 1.69 1.43e−04
GOTERM_MF_ALL phospholipid binding 9 1.52 .0194455
GOTERM_MF_ALL structural constituent of cytoskeleton 9 1.52 .0021281
GOTERM_MF_ALL copper ion binding 7 1.18 .0135518
GOTERM_MF_ALL prenylated protein tyrosine phosphatase activity 7 1.18 .0067538
GOTERM_MF_ALL growth factor binding 7 1.18 .0039932
GOTERM_MF_ALL kinase regulator activity 6 1.02 .0347643
GOTERM_MF_ALL tubulin binding 5 0.85 .0403221
GOTERM_MF_ALL dioxygenase activity 5 0.85 .0134921
GOTERM_MF_ALL insulin-like growth factor binding 5 0.85 .0029651
GOTERM_MF_ALL L-ascorbic acid binding 5 0.85 5.08e−04
GOTERM_MF_ALL integrin binding 4 0.68 .0426353
GOTERM_MF_ALL actin filament binding 4 0.68 .0043206
GOTERM_MF_ALL low-density lipoprotein binding 3 0.51 .0283400
GOTERM_MF_ALL Ras GTPase activator activity 3 0.51 .0283400
GOTERM_MF_ALL lipoprotein receptor activity 3 0.51 .0151426
GOTERM_MF_ALL low-density lipoprotein receptor activity 3 0.51 .0115423
GOTERM_MF_ALL oncostatin-M receptor activity 2 0.34 .0482958
BBID 12.IL-6_type_cytok-signal-transduct 4 0.68 .0203501
BIOCARTA h_prionPathway: Prion Pathway 4 0.68 .0103901
BIOCARTA h_il10Pathway: IL-10 Anti-inflammatory Signaling Pathway 4 0.68 .0080196
BIOCARTA h_reckPathway: Inhibition of Matrix Metalloproteinases 4 0.68 .0060027
BIOCARTA h_akap13Pathway: Rho-Selective Guanine Exchange Factor AKAP13 Mediates Stress Fiber Formation 3 0.51 .0290874
COG_KOG_ONTO LOGY Cell division and chromosome partitioning 12 2.03 .0107010
